Microfluidic technologies for capturing and concentrating human immunodeficiency virus-1 (HIV-1) particles. by McArthur, Chanelle Crystal.
MICROFLUIDIC TECHNOLOGIES FOR CAPTURING 
AND CONCENTRATING HUMAN 









Master’s Dissertation by 
Chanelle Crystal Mc Arthur 
 
 
For the Degree of 
Master of Medical Science, 2016 
 
Submitted in partial fulfilment of the requirements for the degree of Master of Medical 
Science (MMDSC) in school of Laboratory of Medicine and Medical Science, University 
of KwaZulu-Natal 
 
Student number: 209503308 






I remember being with my dad in the berg climbing a mountain and moaning how tired I was and how 
I couldn’t climb this mountain anymore. To this day I vividly remember his words, “if you lift up your 
foot, God will put them down.” Little did he know how much those words would mean to me, but here 
I find myself, I kept lifting my feet and have found them placed firmly in a blessing. 
I would like to use this opportunity to express my heartfelt gratitude to my dad, Howard Mc Arthur, 
who gave me the opportunity to go to university and gain an education. To my mom, Dominique Mc 
Arthur, for being there emotionally when I phoned her at times, in tears.  
I would like to sincerely thank my supervisor, Dr Frederick Balagaddé, who has given me this 
opportunity to be in a very rich scientific community within K-RITH, but more specifically to have 
provided me with not just skills of the work place, but something much greater…life skills. Learning 
how life works, within academics and outside has been a treasure nobody can cheat me of. To everyone 
in Frederick’s lab, thank you for not just being colleagues, but being my friends and family. I look 
forward to many more tea trips to the kitchen and our break time discussions.  
The financial assistance from the Kwa-Zulu Natal Research Institute of TB and HIV (K-RITH) towards 
this research is hereby acknowledged. 
 
“Everybody is a genius. But if you judge a fish by its ability to climb a tree, it will live its whole 
life believing that it is stupid”- Albert Einstein  















I, Chanelle Crystal Mc Arthur, hereby declare that this thesis entitled 
 
“MICROFLUIDIC TECHNOLOGIES FOR CAPTURING AND CONCENTRATING 
HUMAN IMMUNODEFICIENCY VIRUS-1 (HIV-1) PARTICLES.” 
 
This work is the result of my own investigation and research and that it has not been submitted in part 
or in full for any other degree or to any other university. Where use was made of the work of others, it 




Name:         Signature: 
 









           Chanelle Mc Arthur            CCM






HIV-1 RNA assays are routinely used in developed countries to monitor the effectiveness of 
antiretroviral therapy (ART)1. These assays require well-trained operators, expensive equipment and 
reagents, and established laboratory infrastructure1. These requirements limit their usefulness in 
resource-limited settings where people are most afflicted by the HIV-1 epidemic1. Recent advances in 
microfluidics and nanotechnology offer new approaches for rapid, low-cost, robust and simple HIV-1 
viral load monitoring systems1. Here we describe an approach within a microfluidic device to directly 
detect HIV-1 virus particles using an immune sandwich assay that includes anti-gp120 antibodies -
conjugated to polystyrene microspheres and fluorescently labelled goat anti-HIV-1 FITC detection 
antibodies. The anti-gp120 antibody-conjugated microspheres were employed to capture and 
concentrate HIV-1 particles, whereas the FITC detection antibodies were used to generate fluorescent 
signal that represented the number of captured viruses. In the presence of HIV-1 particles, addition of 
microspheres and FITC detection antibody led to the formation of a microsphere/HIV-1 particle/FITC 
detection antibody complex. This complex was measured by analysing the fluorescence intensity 
produced by the FITC detection antibody bound to the HIV-1 particle within the complex. We 
demonstrated the utility of an in-house microfluidic device and assay in detecting 1x106 virus 
particles/µl with a significance of (p≤0.01). This assay was completed within 3.8 hours, without any 
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Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) has caused 
approximately 25 million deaths since it was first discovered in 19812. In addition, there is an estimated 
40 million people currently living with HIV-1 worldwide3. Of them, 97% are individuals living with 
HIV-1 in developing and moderate-income nations4. Of these 97% infected people, sub-Saharan Africa 
makes up 70%5. Closer to home, South Africa remains one of the most burdened countries with one in 
every 10 South Africans living with HIV-16 compared to only 2 in every 1000 individuals living with 
HIV-1 in the United Kingdom7. Typically, patients in heavily burdened areas have very limited 
resources and insufficient access to ART which can help suppress HIV-1 replication cycle and delay 
disease progression2. To curb this pandemic and to save lives, the World Health Organization (WHO) 
has rapidly started expanding access to ART in developing countries, originally aiming at universal 
access by the year 20102. However, this has more challenging than originally envisioned since out of 
15 million people needing ART in 2011, only 9.7 million had access to ART in low- and middle-income 
countries by the end of 2012, partly due to the lack of cost –effective ART administration and 
monitoring8. 
 
Currently, there are two major approaches to monitoring the effectiveness of HIV-1 ART. HIV-1 viral 
load in plasma, which indicates viral replication in the infected individual and CD4+ T lymphocyte 
count, which provides information on the functionality of the patient’s immune system2. In developing 
areas, for individuals undergoing ART therapy, these parameters are not as regularly monitored 
compared to developed areas. These parameters are typically monitored once a  year, whereas in 
developed areas, they are monitored every 3-6 months2. HIV-1 viral load is often monitored using 
commercial ribonucleic acid (RNA) assays, such as the reverse transcriptase-quantitative polymerase 
chain reaction (RT-PCR) for example Roche COBAS®, whereas CD4+ cell count is monitored using 
flow cytometry2. However, the application of such assays requires highly skilled personnel, high cost 
equipment (e.g., thermal cyclers) and expensive reagents [US$ 50-100 (ZAR 765-1,530) per test], 
which is not feasible for widespread application in resource-limited settings2. Due to the lack of viral 
load monitoring in developing areas, the WHO recommended a CD4+ cell count guideline for when to 
initiate ART in resource-limited settings. ART should be initiated when an individual has a CD4+ cell 
count of 500 cells/mm3 or less9. Unfortunately, this WHO guideline has often lead to the late 
identification of virological ART failure. This may then allow for the accumulation of drug-resistant 
strains and reduce the efficacy of subsequent ART regiments2. Therefore, there is a need for affordable 




Some inexpensive alternatives to RNA viral load assays have been developed such as ExaVirTM RT 
viral load assay version 2.0 and in-house real-time reverse transcription quantitative-polymerase chain 
reaction (RT-qPCR) such as the BioMerieux NucliSens® 2. However, these assays still have some 
drawbacks that limit their widespread use. For example, despite the reduced costs [approximately US$ 
20 (ZAR 313) per test] the assays still require skilled operators and air conditioned laboratory 
conditions. These methods may be appropriate for centralized laboratories, but not for district clinics in 
resource-limited settings. The ExaVirTM RT viral load assay version 2.0 demonstrated good 
acceptability in a district hospital laboratory in Botswana, but there were some limitations2. The 
throughput of this assay was low, with a turnaround time of 2 days and up to 180 samples per week 
analysed. Other approaches resource-limited setting utilize to test patient’s viral load include; sending 
samples elsewhere for analysis, dried blood spots (DBS) and viral load pooling. All of these assays still 
require the use of polymerase chain reaction (PCR)10,11. Therefore, recent advances focus on developing 
portable detection systems towards the point-of-care (POC) setting2. 
 
Recently, nano/microfluidic technologies have emerged as a powerful tool for the diagnosis and 
monitoring of infectious diseases, such as HIV-1, in both the developed and developing regions. 
Miniaturized microfluidic platforms enable the manipulation of small fluid volumes that can be useful 
for diagnosing patients in a more rapid and accurate manner that may also be more affordable. In 
particular, microfluidic diagnostic technologies are applicable within the global health sector, since they 
are typically inexpensive, portable, disposable, and easy-to-use2.  
 
Within this dissertation we review HIV/AIDS and HIV-1 viral load assays found in developed and 
developing countries. We also review how microfluidic technology is emerging as a potentially valuable 
approach for monitoring HIV-1 viral load of patients. Lastly, we demonstrate a pioneering effort that 
involved the construction, use and investigation of a microfluidics device for capturing, concentrating 
and quantifying HIV-1 particles. 
 
The dissertation is composed of the following chapters; 
 
Chapter 1: The core purpose of this chapter is to provide a concise literature overview of HIV/AIDS, 
ART, viral load monitoring techniques used in both developed and developing regions, and the 
advancement of microfluidics.   
 
Firstly, the history of the development of HIV/AIDS via successful transmission of the simian 
immunodeficiency virus (SIV) to humans is discussed. From here, a description of how HIV infection 
leads to the immune system becoming vulnerable to opportunistic infections through the destruction of 
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the CD4+ immune cells leading to AIDS. Backgrounds on both HIV-1 and HIV-2 is explained, 
outlining the different phylogenetic lineages. Next presented, is the structure and life cycle of HIV-1. 
Then, how the development of ARV drugs exploit the life cycle of HIV-1, prohibiting certain stages of 
the life cycle. Thereafter, the relationship between HIV-1 burden and GDP of particular regions and 
countries is shown, bringing to light that those settings most highly burdened by HIV-1 have the least 
amount of resources to purchase ARV drugs and monitor the disease. Furthermore, we review the 
literature on how the lack of ARV monitoring availability in developing regions in particular, has led 
to the high risk of mother-to-child transmission (MTCT). Next, we define viral load monitoring and the 
production of diagnostic markers at certain stages during the natural course of HIV-1 infection. These 
markers, through the use of particular monitoring assays such as ELISA, PCR and flow cytometry 
assays are vitally important to measure. Thereafter, we discuss scientific techniques viral load 
monitoring assays often employ to determine viral load. These techniques include either; enzyme-linked 
immunosorbent assays (ELISAs), PCR or flow cytometry, providing both advantages and 
disadvantages of these techniques. From here we provide a review of current HIV-1 viral load assays 
for developed countries such as; COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test and RealTime 
HIV-1 assay. We then discuss alternative HIV-1 screening methods and approaches in resource-
constrained settings such as DBS, sample pooling, Cavidi ExaVir™ RT assay, PerkinElmer 
Ultrasensitive p24 assay and lastly in-house RT-qPCR assays. The final section of the literature review 
discusses microfluidics. This chapter explains the fabrication process of microfluidics, advantages, 
limitations, current microfluidic technology applications and advances in HIV-1 POC viral load in 
resource-limited settings using microfluidics. To finish, Chapter 1, the aims and objectives of the 
dissertation is outlined.  
 
The remainder of the chapters, Chapters 2-5 are devoted solely to the materials, methods, results, 

















In 1981, the first cases of an AIDS were reported among young, homosexual American men12, 
heralding what we now know to be the beginning of the HIV/AIDS epidemic. AIDS can be caused 
either by HIV-1 or HIV-2, both of which are derived from a clade of the Lentivirus genus (SIV) of the 
Retroviridae family found naturally in more than 40 species of nonhuman primates in sub-Saharan 
Africa. SIV predominantly falls into host-specific clades, but has occasionally “jumped” species and 
successfully spread to new hosts3. Successful transmission of one particular strain of SIV from the 
chimpanzee subspecies (Pan troglodytes troglodytes) to humans lead to the development of HIV3. 
 
HIV infection causes an acquired immunodeficiency, primarily as a result of the depletion of CD4+ T 
cells. CD4+ T cells are a type of white blood cell that plays a crucial role in protecting the body from 
infection13. The mechanism by which the virus depletes these CD4+ cells, however, is not quite clearly 
understood14 although apoptosis has been proposed as a key mechanism15. A study done by Gilad Doitsh 
et al., showed that apoptosis of the CD4+ T cells only accounts for the death of a very small fraction of 
the CD4+ cells that are both activated and infected. The remaining 95% of quiescent CD4+ T cells die 
due to pyroptosis, triggered by the viral infection15. Pyroptosis corresponds to an inflammatory form of 
cell death whereby inflammatory cytokines are released. This release of cytokines leads to two signature 
events in HIV infection, CD4+ T cell depletion and chronic inflammation. This further creates a vicious 
cycle whereby dying CD4+ T cells release inflammatory signals that further attracts more cells to die15. 
Over time the CD4+ cell count declines and eventually there are not enough CD4+ cells remaining to 
defend the body from opportunistic infections16. The patient at this point becomes highly susceptible to 
any opportunistic infection such as pneumonia, bacterial sepsis and tuberculosis17. Once a patient has 
reached this stage, the patient is said to have AIDS. Both the virus and the syndrome together are 
sometimes referred to as HIV/AIDS18.  
 
HIV is categorized into two types, HIV-1 and HIV-2. HIV-1 evolved from a SIV found in African apes3 




HIV-1, the causative agent of AIDS, is composed of three major phylogenetic groups20. These groups 
include groups M, O and N, each of which resulted from an independent cross-species transmission 
event of the SIV3. Group M, the cause of the AIDS pandemic, has spread across Africa and throughout 
the rest of the world infecting more than 40 million individuals3. More than 90% of all HIV-1 infections 
are derived from group M. Group O is mainly restricted to west central Africa, having spread through 
Gabon, Nigeria, Cameroon, and other neighbouring countries. Group O has been estimated to have 
infected approximately 100,000 individuals3 and represents 1-5% of HIV-1 infections20. Lastly, group 
N viruses have been identified in a limited number of individuals from Cameroon.  
 
HIV-2, was first discovery around 198921. Initially confined to West Africa, specifically Senegal and 
Guinea-Bissau21, has since spread to Europe, India, and the United States22. An estimated 1-2 million 
HIV-2 infected people are found in West Africa22. However, in recent years the overall prevalence rate 
of HIV-2 has started declining, and in most West African countries, HIV-2 is being replaced by HIV-
1. For example, in a rural area of north-western Guinea-Bissau in West Africa, the prevalence of HIV-
2 dropped from 8.3% in 1990 to 4.7% in 2000. During the same time period, the HIV-1 prevalence in 
this region increased from 0.5% to 3.6%22. This trend may be related to the 5-fold lower rate of sexual 
transmission of HIV-2 compared to HIV-1, making HIV-2 less infectious than HIV-123. HIV-2 viral 
load levels are also typically lower compared to HIV-1 infected individuals21. In untreated patients, 
viral load levels of HIV-2 tend to be approximately around 10,000 copies/mL, versus sometimes 
millions of copies/mL in HIV-1 infected individuals24. Lastly, it has been documented that most 
individuals infected with HIV-2 typically do not progress to AIDS21, due to the aforementioned 
characteristics of HIV-2. 
 
A detailed understanding of HIV-1 structure and how it establishes infections and causes AIDS is 
crucial not only to be able to identify and develop new effective vaccines and drugs, but also to define 
strategies for laboratories to diagnose HIV-1 infection. Diagnostic strategies have to be continuously 
reviewed according to new discoveries on the replication characteristics of HIV-1 infection25. 
 
1.1.1. HIV-1 Structure 
 
The retrovirus genome is composed of two identical copies of single-stranded RNA molecules and is 
characterized by the presence of the following structural genes; gag, pol and env. In addition to these 
structural genes, there are regulatory genes; tat and rev and accessory proteins; Vpr, Vpu, Vif and Nef 








Figure 1: Organisation of the HIV-1 genome, highlighting the structural genes; gag, pol and env, the 
regulatory genes; tat and rev and the accessory proteins; Vpr, Vpu, Vif and Nef25. 
 
 
The gag gene encodes the structural proteins of the core (p24, p7, p6) and the matrix (p17). The env 
gene encodes the viral envelope glycoproteins gp120 and gp41, which recognize the host cell’s surface 
receptors25. Lastly, the pol gene encodes for enzymes that are crucial for replication. These enzymes 
include the reverse transcriptase (RT) enzyme that converts viral RNA into DNA, the integrase enzyme 
that incorporates the viral DNA into the host cells chromosomal DNA (known as the provirus) and 
lastly, the protease enzyme that cleaves large Gag and Pol protein precursors, which is necessary for 
the generation of infections viral particles25.  
 
The regulatory genes tat and rev and the accessory proteins; Vpr protein, Vpu protein, Vif protein and 
Nef protein (Figure 1) play a key role in modulating viral replication25. The tat gene encodes for the 
protein (Tat) which is expressed soon after infection and promotes the expression of HIV genes. The 
rev gene encodes for the Rev protein, which helps exports processed genomic RNA from the cell 
nucleus to the cytoplasm. The accessory protein Vpr is involved in the arrest of the cell cycle, enabling 
the reverse transcribed DNA to enter the nucleus of the host cell25. Vpu protein is necessary for the 
correct release of virus particles, whereas the Vif protein enhances the infectiveness of the progeny 
virus particle. Lastly, the Nef protein is involved in the down regulation of the CD4+ cell receptor on 
the cells surface in order to allow virus budding in the late stages of the virus replication cycle25. 
HIV-1 particles have a diameter of 100 nm and are surrounded by a lipoprotein-rich membrane (lipidic 















Figure 2: Structure of HIV-1 particle highlighting the core protein (p24) encoded by the gag gene, 
glycoproteins gp120 and gp41 encoded by the env gene and reverse transcriptase enzyme encoded by 
the pol gene. ssRNA: single strand RNA25. 
 
 
The lipidic membrane consists of glycoprotein complexes composed of triers of the external surface 
gp120 and the transmembrane spanning gp41 glycoproteins bound together25. The binding between the 
gp120 and gp41 is not covalent and so gp120 may shed spontaneously and can be detected in the serum. 
Anchored within the inside of the viral lipidic membrane is the matrix protein (p17). Both this 
membrane and matrix protein house the viral capsid, which is composed of polymers of the core antigen 
(p24). The capsid contains two copies of HIV RNA and the enzymes RT, integrase and protease25.  
 
1.1.2. HIV-1 Life Cycle 
 
The HIV-1 life cycle, as shown in Figure 3, can be described in six steps; 1: binding and entry; 2) 
uncoating; 3) reverse transcription; 4) provirus integration; 5) virus protein synthesis and assembly and 



























Figure 3: The 6 steps of the HIV-1 replication cycle; 1: binding and entry; 2) uncoating; 3) reverse 
transcription; 4) provirus integration; 5) viral protein synthesis and assembly and lastly, 6) budding25.  
 
 
1) Binding and Entry 
 
The entry pathway of HIV-1 is divided into three major events: the virus binding to the cell, 
fusion and entry. The viral envelope trimeric complex, composed of gp120 and gp41, are vital 
for the virus recognition and entry into target cells (CD4+ T cells)25. The gp41 subunit contains 
a fusogenic peptide that is essential for fusion of the viral and host cellular membrane. HIV 
gp120 binds to a glycoprotein CD4, which is expressed on the surface of approximately 60% 
of the circulating T-lymphocytes25. Upon gp120 binding with the CD4 protein, the virus 
envelope complex undergoes a structural change. This change, exposes a specific domain in 
the gp120 that is capable of binding to chemokine receptors (coreceptors) on the host cell 
membrane. The coreceptors used by HIV-1 are either CXCR4 or CCR5. Some strains of HIV-
1 bind to the coreceptor CCR5, which are mainly presented in macrophages and CD4+ T cells 
expressing CCR5 and are therefore known as macrophagetropic (M-tropic)25. CCR5 is the 
mostly commonly used corecptor. Other viral strains of HIV-1 use CXCR4 corecptor in primary 
CD4+ T-cells that express CXCR4, therefore are known as T-lymphocyte-tropic (T-tropic) 
viruses. Interestingly, some HIV-1 isolates are able to bind to both CCR5 and CXCR4 receptors 



















The binding of gp120 to both the CD4 and one of the coreceptors allows a more stable 
attachment of the virus. This in turn allows the gp41 fusogenic peptide to penetrate the host 
cell’s membrane and bring both the virus and cell membrane closer together. This then allows 




Once membrane fusion has occurred and the viral capsid has been injected into the host cell, 
the capsid uncoats in the cytoplasm of the host cell and releases the viral RNA25. 
 
3) Reverse Transcription  
 
The viral RNA is then converted into proviral double helix DNA molecule by the RT enzyme25. 
 
4) Provirus Integration 
 
Next, the integrase enzyme cleaves the ends of the double helix DNA creating sticky ends and 
transports the modified provirus DNA into the cell nucleus. From here, integrase helps facilitate 






5) Viral Protein Synthesis and Assembly 
 
Once the provirus is within the host genome, it will only be expressed when or if the host cell 
becomes activated. Only upon activation will the transcription of proviral DNA into messenger 
RNA occur. Transcription results in the synthesis of regulatory HIV-1 proteins (Tat and Rev) 
as well as the production of the structural proteins from the structural genes for the new 
virions25. 
 
The assembly of a new viral particle by is a stepwise process. The two viral RNA strands 
associate together with the viral enzyme, while core proteins assemble over them, making the 
virus capsid. At this point the virus is termed an immature particle. The immature particle 
migrates towards the cell surface, whereby the protease enzyme cleaves molecules on this 
immature particle, resulting in a new infectious viral particle. This infectious viral particle will 




During this final stage, the newly assembled viral progeny bud from the cell by fusing with the 
host cell membrane. This often results in the virus lipid membrane incorporating some host cell 
proteins and it becomes enriched with cholesterol and lipids. The budding process doesn’t kill 
the host cell immediately, but over time, the more damaged the cell membrane becomes from 
all the budding processes, the cell will die25. 
 
By having a detailed understanding of the above HIV-1 structure and life cycle, it enables scientists to 
identify and develop new effective vaccines and drugs. The advancement in the management of HIV-1 
infection has been the treatment of patients with ARV drugs. These drugs are capable of suppressing 
the HIV-1 replication cycle to undetectable viral load levels26. From the time when the first HIV-1 
specific ARV drugs were given as monotherapy in 1990, the standard of HIV-1 care has since evolved 
to include a cocktail of ARV drugs26. This cocktail of ARV drugs otherwise known as HAART was 
pivotal in reducing morbidity and mortality associated with HIV-1 infection26. From once being 
considered a death sentence, HIV-1 patients who have access to effective HAART now have a near to 






1.2. HIV Disease Burden and the Motivation for more Effective Viral load Testing 
 
1.2.1. Antiretroviral Therapy  
  
The development of drugs for HIV-1 infection commenced soon after the virus was discovered 35 years 
ago. Since then, monumental steps towards the development of drugs that interfere with certain stages 
of HIV-1 life cycle have transpired with unprecedented success. Nearly, 6.6 million HIV/AIDS related 
deaths worldwide have been prevented due to HAART27. HAART consists of a combination of at least 
three drugs8. The most routinely prescribed HAART combination is NNRTI, NRTI and PI as a single 
pill or in various pill combinations28. 
 
Currently, there are 6 major classes of ARV drugs. These classes include; nucleoside analogue reverse 
transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease 
inhibitor (PI). The last 3 classes of ARV drugs includes; fusion inhibitor, chemokine coreceptor 
antagonist (including 2 subclasses: CCR5 and CXCR4 antagonist) and integrase inhibitor29, see Figure 



















Figure 5: The HIV-1 life cycle and the ARV drug classes that disrupt certain processes in the life 









acting like structural analogues of natural nucleosides. Non-nucleoside reverse transcriptase inhibitor 
(NNRTI) completely suppresses the reverse transcriptase enzyme. Protease inhibitor (PI) interferes with 
the final stage of the replication cycle by not allowing the protease enzyme to cleave the gag precursor 
polyprotein, blocking formation of the virus particles. Fusion inhibitors block HIV from entering into 
target cells. Integrase inhibitors prevent the integration of the viral cDNA into the CD4+ cells genome 
by binding to the integrase enzyme and prevents the enzyme functioning. Lastly, chemokine coreceptor 
antagonists disrupt the initial binding of HIV-1 to the CD4+ cell.  The antagonists bind to either the 
CCR5 or CXCR4 coreceptor on the surface of CD4+ cells and blocks a necessary step needed in viral 
entry, preventing HIV-1 entering the cell30. 
 
 
NRTIs function by inhibiting the synthesis of DNA by reverse transcriptase. The nucleoside analogues 
have a structural resemblance to the natural building block of DNA (the nucleosides adenosine, 
thymine, guanosine and cytidine)29. The nucleoside analogues under modification within the cell 
becomes phosphorylated. The reverse transcriptase enzyme of HIV-1 cannot distinguish the difference 
between the natural phosphorylated nucleosides and the phosphorylated NRTIs, and tries to use the 
drugs in viral DNA synthesis29. When the NRTI is incorporated into the strand of DNA being 
synthesised, any further nucleotide additions is prevented and a full-length copy of the viral DNA is 
unable to be produced29. Examples of NRTI drugs include; Zidovudine and Tenofovir31. NNRTI 
completely suppresses the reverse transcriptase enzyme32. It does so by binding to the reverse 
transcriptase in a way that inhibits the enzyme’s activity, thereby inhibiting the synthesis of viral 
DNA29. Examples of NNRTI drugs include Nevirapine and Efavirenz31. PIs interfere with the final stage 
of the replication cycle by not allowing the protease enzyme to cleave the gag precursor polyprotein, 
blocking formation of the virus particles32. PIs do this by binding to the active site of the viral protease 
enzyme. This prevents processing of the viral proteins into functional conformations. The viral particles 
are still produced despite the protease enzyme being inhibited, but they are not effective at infecting 
new cells29. Examples of PIs are Ritonavir and Indinavir31. Fusion inhibitors (entry inhibitors) block 
HIV-1 from entering into target cells. Drugs within this class bind to the HIV-1 envelope protein gp41. 
Envelope protein gp41 is involved in viral entry, but when fusion inhibitors block gp41, they interfere 
with the conformational change of the envelope molecule needed for fusion with the host cell 
membrane29. Examples of fusion inhibitor drugs are Enfuvirtide and Maraviroc31. Integrase inhibitors 
prevent the integration of the viral cDNA into the CD4+ cells genome32 by binding to the integrase 
enzyme and preventing the enzyme from functioning29. Examples of integrase inhibitors include 
Raltegravir and Elvitegravir31. Lastly, there are chemokine coreceptor antagonists that disrupt the initial 
binding of HIV-1 to the CD4+ cell. These antagonists bind to either CCR5 or CXCR4 coreceptor on 
the surface of CD4+ cells, blocking a necessary step needed in viral entry thereby preventing HIV-1 
entering the cell29. Examples of a chemokine coreceptor drug is Selzentry33.  
13 
 
Even with the advancement in ARV drugs, the development of drug resistance is a natural biological 
process that will occur over time34. With the on-going use of HAART, the rate of HIV-1 infection can 
be dramatically reduced. However, HAART is not a cure for HIV17 as there are numerous reasons why 
HIV-1 cannot be eradicated with current drug therapy. Reasons such as high HIV-1 mutation rates, 
production of thousands of virion progeny and viral reservoirs, which all play a role in the inability of 
HAART from becoming a cure. The extensive heterogeneity observed in the HIV-1 epidemic originates 
from the rapid viral turnover of 1x1010 viral particles produced per day in an infected individual. This 
causes a high rate of incorrect nucleotides being substituted during HIV-1 reverse transcription, leading 
HIV-1 having a high mutation rate of 3 x 10-5 mutations per base pair, per replication cycle35 (which 
occurs every 2-3 days36). Comparing this mutation rate to that of the Ebola virus, which has a nucleotide 
substitution rate of 1.3x10-3 substitutions per year37. Besides from the high HIV-1 mutation rate which 
poses a challenge for ARV therapy, the virus targets and replicates within many different immune-
system cell types17. Treatments that can inhibit HIV-1 replication in one particular cell type may not be 
able to inhibit replication in another type17. Once an immune cell is infected by a single HIV particle, 
thousands of copies of the virion can be produced before the cell is destroyed. The virus also hibernates 
in a variety of reservoirs throughout the body and long-term remission requires continued control over 
the immune cells that are vulnerable to infection for the rest of the patient’s life17. If the patient stops 
therapy, HIV-1 within the reservoirs becomes active again. These natural biological process of 
resistance development have also been accelerated due to human practices such as non-adherence, 
treatment interruptions, lack of HIV-1 monitoring and the prescription of incorrect drug regimens34. 
The main aim for current HIV-1 therapy is to break the replication cycle, which should lead to 
diminished replication events that occur and thereby lowering the viral load levels. This should aid the 
therapy regime to remain effective in the long run. 
 
There has been evidence that the rate of transmitted drug resistance of HIV-1 has become less detected 
in more developed countries compared to developing countries. For example, the rate of transmitted 
drug resistance of HIV-1 to NNRTI in Canada is 1.6%38, whereas the rate of transmitted drug resistance 
of HIV-1 to NNRTI in KwaZulu-Natal, South Africa is 5-15%39. There has also been a trend observed, 
that areas with a higher disease burden also have a lower literacy rate.  For example, in 2011 Canada 
had a literacy rate of 99%, the highest in the world40 and 71 300 people living with HIV-141. This is in 
contrast to Chad (a Sub-Saharan Africa country) which only has a literacy rate of 34.5 %42, but has 210 
000 individuals living with HIV-1 in 201143. The reason for Canada, a developed country, having less 
HIV-1 infected individuals, is due to both a high standard of healthcare systems and seemingly a more 
advanced educational system, whereby the importance of ARV and HIV-1 may be more widely known, 
compared to resource-limited settings. Most developed countries have implemented routine use of viral 
load testing in order to monitor how effective a patients HAART combination is and if it is successfully 
keeping the patient’s viral load low11. Despite the rapid increase and efforts of the WHO to provide 
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access to ART worldwide, in low-and-middle income countries, viral load testing is still fairly rare due 
to the high costs. This often leads to a patient remaining on a standard fixed-dose HAART 
combination11 for a prolonged period of time, until their viral load can be tested. Despite this approach 
allowing for a higher chance of a patient adhering to their therapy regime44, it can also lead to drug 
resistance. Lastly, the price of ARVs poses another hurdle within the disease management system. In 
the year 2013 for low-and-middle income countries, the cost of ARV therapy varied depending on 
which regimen the patient was receiving. For first-line, second-line and third-line treatment, the price 
of therapy was US$ 115 (ZAR 1,753), US$ 330 (ZAR 5,031 ) and US$ 1 500 ( ZAR 22,871)  per year, 
per patient, respectively45. Due to the high cost of HAART, in sub-Saharan Africa countries with low 
GDPs, such as Nigeria, only 20% of HIV-1 patients have access to ARV treatment46. This in contrast 
to a country which has a higher GDP, such as Australia, whereby 100% of HIV-1 positive patients have 
access to ARV treatment47. 
 
1.2.2. Relationship between HIV-1 Burden and GDP (per capita)  
 
Low-and-middle incomed countries struggle to cope with the HIV-1 disease burden and this can be 
seen through the GDP of these areas. By analysing the number of HIV-1 infected individuals in 
particular places around the world relative to the GDP, an inversely proportional relationship becomes 
























Figure 6: Bubble plot highlighting HIV-1 burden of a specific countries and their corresponding GDP 
per capita. The size of the bubbles represents the amount of people currently living with HIV-1 
(millions) in red or the GDP (per capita) (USD) (thousands) in blue. Some regions around the world are 
heavily burdened with HIV-1, having little GDP to manage, such as Sub-Saharan Africa. In 
contradiction, countries such as Australia where the HIV-1 burden is less, the income is high. (Graph 
made from information collected from UNAIDS46. 
 
 
From Figure 6, one can see a large disproportionality of incomes which adds to the HIV/AIDS epidemic. 
Poorer countries are most heavily disease burdened, but cannot afford the necessary interventions. For 
instance, Australia has one of the highest GDP per capita but, has one of the lowest HIV-1 burdens. 
This is in stark contrast to sub-Saharan Africa which represents nearly 70% of the total number of 
people living with HIV/AIDS globally5 and has a low GDP per capita, thus scarcer resources to cope 
with the disease burden. 
 
Found amongst the low GDP and heavily HIV-1 disease burdened sub-Saharan Africa were 2.9 million 
children living with HIV-1 in 2013. Only 24% of these children received ART, resulting in 190 000 











for adequate testing, paediatric ARV drugs and prevention of mother to child transmission (MTCT) 
programs, this results in children having to continue suffering from the epidemic.  
 
1.2.3. Prevention of Mother to Child Transmission (PMTCT)  
 
Pregnant women are an important group to target for HIV-1 prevention49. With early diagnosis and viral 
load levels quantified, appropriate management of MTCT through HAART usage can reduce MTCT 
by approximately 40%50. 
 
MTCT refers to the transmission of HIV-1 from a woman who is HIV-positive to her child during 
pregnancy, labour, delivery or breastfeeding. MTCT is the main means by which most children acquire 
HIV-1. Over 90% of new HIV-1 infections in infants and young children occur through MTCT in low- 
and middle- income countries51. With approximately 37 million individuals living with HIV-1 at the 
end of 2014, sub-Saharan Africa accounted for approximately 26 million out of the 37 million people 
living with HIV-1. Amongst the 26 million HIV-1 individuals in sub-Saharan Africa, 55% were 
women52,  which increases the risk of MTCT. In Uganda alone, 96 700 babies were born to HIV-positive 
mothers in 2011 and 20 600 (21%) of them contracted HIV-1 during birth from their mothers via 
MTCT53. In the absence of medical intervention, prior to the birth of the child by an HIV-positive 
mother, the risk of HIV-1 transmission to the child, without breastfeeding is between 15-30%. If the 
mother breastfeeds the child after birth, the transmission risk increases to 20-45%54. The risk of MTCT 
at birth can be dramatically reduced to fewer than 2%, if the necessary interventions are implemented.  
 
These interventions are collectively termed as PMTCT. PMTCT strategies include; HIV-1 testing and 
antiretroviral prophylaxis, which is given to the HIV-positive mother during pregnancy and labour, as 
well as to the new-born infant in the first few weeks of its life. Other PMTCT strategies include an 
elected caesarean delivery before the onset of labour (prior to the membranes rupturing) and total 
avoidance of breastfeeding. These interventions are routinely practiced in high-income countries, 
lowering the risk of new HIV -1 infections in children dramatically54. This was evident between the 
year 2009 and 2013, whereby PMTCT interventions averted a total of 900 000 new HIV-1 infections 
in children, mainly in high income countries55. However, PMTCT interventions such as breastfeeding 
avoidance are seldom feasible in resource-limited settings due to many deterring factors such as, safe 
running water and the cost of infant formula -breast milk substitute- itself is exorbitant. If we consider 
women in South Africa, where the unemployment rate is more than 30%, most cannot afford breast 
milk substitutes. Another deterrent for preventing the practice of breastfeeding is the access of formula. 
For instance, women in rural areas often have to travel 10 to 15 kilometres with little to non-transport 
being available to access the infant formula56. One of the most crucial points of PMTCT to be decreased, 
is the deficiency of ARV coverage in rural areas. As previously stated, out of 15 million people needing 
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ART in 2011, only 9.7 million had access to ART in low- and middle-income countries by the end of 
2012, partly due to the lack of cost –effective ART monitoring8. With little testing and ARV coverage, 
the MTCT rate during labour and delivery accounts for two-thirds of overall transmissions in infants in 
resource-limited countries54. To make PMTCT effective on a long-term basis, HIV-1 testing needs to 
be carried out more extensively and regularly for pregnant women. This will enable timely 
administration of PMTCT interventions for HIV-positive mothers. PMTCT efforts in resource-limited 
areas increases the need for drug susceptibility and HIV-1 testing for high-risk mothers prior to delivery.  
 
As seen, for ART therapy to be useful for both individuals and mothers-to-be, monitoring viral load is 
of utmost importance to evaluate if treatment is effective by keeping a low viral load. For viral load 
testing to be carried out, certain markers produced during the natural course of HIV-1 infection must 
be measured.  
 
1.2.4. Markers for HIV-1 Viral load monitoring.  
 
The natural course of HIV-1 infection can be divided into 3 stages. These stages are, seroconversion, 
asymptomatic and symptomatic stages. At each of these stages, different diagnostic markers are found 
that can be used to gauge ART efficacy. These diagnostic markers include; HIV-1 RNA, DNA, antigen, 








Figure 7: Diagnostic markers during the natural course of HIV-1 infection57. During the three stages of 
HIV-1; Seroconversion, asymptomatic and symptomatic, certain markers are produced that can be 
measured. During seroconversion, HIV-1 RNA (red line) peaks, but then decreases and remains at a 
low level, showing no clinical symptoms. HIV-1 p24 antigen (blue triangle) follows the same trend as 
HIV-1 RNA. HIV-1 specific antibodies (green circles) are produced during seroconversion, reaches a 
plateau during the asymptomatic stage and decreases in the symptomatic stage.CD4+ cells (black 
squares) drip rapidly and rebounds during seroconversion. Slowly over the course of infection the CD4+ 
cell number decreases as AIDS develops2.  
 
 
Viral load can be defined as the level of HIV-1 RNA in plasma (copies/mL)2. Soon after infection, the 
level of HIV-1 RNA increases significantly and reaches a peak of approximately 107 copies/mL (Figure 
7). Almost immediately after infection, the immune system starts producing antibodies to control the 
virus. This stage is known as seroconversion and can take between three weeks to three months. During 
this stage, the host immune system is still intact, represented by a high CD4+ cell count. After 
seroconversion is the asymptomatic stage. This is when the individual shows no signs or symptoms that 
they are infected and they may even have at this point. An undetectable viral load means that there is 
little HIV-1 in their blood for a diagnostic device to detect58. This stage can last many years and during 
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this stage, the HIV-1 viral load is kept at a low level throughout. However, HIV-1 towards the end of 
this stage starts to slowly compromise the host immune system, indicated by a decrease in the CD4+ 
cell count2. HIV-1 p24 antigen has also been used as a surrogate marker for viral load monitoring in 
developing countries. As shown in Figure 7, the level of p24 antigen is highly correlated with HIV-1 
RNA (viral load) throughout the natural course of HIV-1 infection. In addition to p24 antigen levels, 
RT levels have a close correlation with HIV-1 RNA in patients as well and can be used as a marker for 
viral load monitoring2. After the asymptomatic stage, people move into the symptomatic phase. Within 
this stage, early symptoms start developing such as, fatigue, weight loss and thrush. Over time, the 
CD4+ cell count continues to drop and the individual develops AIDS, whereby they are being infected 
with opportunistic infections58. 
 
CD4+ cell count has also been termed as a surrogate marker for HIV-1 disease progression. A study 
done by Alison. M. Morris et al.,2000; showed that as viral load decreased, CD4+ cell count increased 
(Figure 8)59. In another study done by Eaton C et al.,2011 the opposite relationship was shown, whereby 
















Figure 8: Time course comparing viral load with CD4+ count and CD8+ Count. As viral load 
















Figure 9: Graph of CD4+ cell count and HIV-1 viral load. As viral load increased over the years, the 
CD4+ cell count decreased60. 
 
 
These above mentioned markers are measured by specific assays in order to continuously monitor a 
patient receiving therapy. These specific assays vary though, depending on the location they are carried 
out in. Developing areas often cannot afford the assays that are performed in developed areas and 
therefore have had to adapt their assays or techniques for monitoring of HIV-1 patients. The accurate 
and timeous detection of HIV-1 infection is vital in allowing the patient’s receiving of timely access to 
both care and drug therapy. This ultimately helps to improve overall treatment outcome61. There is a 
growing demand within the global health community for ways to both simplify and improve the 
efficiency of HIV/AIDS diagnosis without lessening the quality of patient care61. At the same time, 
there is a need to increase the level of access to high-quality and robust diagnostic solutions in resource-
limited settings. This facilitates the prevention of HIV-1 transmission through early detection and 
treatment61. 
 
1.3. Viral load monitoring  
 
Viral load monitoring is the measurement of either; HIV-1 RNA in a patient’s plasma; the number of 
virus particles in a patient’s blood (particles/mL)62 or even the CD4+ cell count (number of cells/mm3)  
can be used to monitor patients. The viral load measurement indicates how effective the HIV-1 patient’s 
HAART therapy is. Typically viral load is measured in copies/mL. For a patient who is on HAART 
therapy, a high viral load is considered to be between 5 000 to 10 000 copies of RNA/mL or anything 
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above, whereas a low viral load is usually between 40 to 500 copies of RNA/mL63.  For CD4+ cell 
count, a normal CD4+ cell count ranges from 500 – 1 500 cells/mm64. Anything below 500 mm3 and 
the individual, if HIV-positive, must be placed on HAART. Anything below 200 cells/mm3 indicates 
serious immune damage and is a sign of AIDS within individuals who are HIV-positive65.  
   
Viral load monitoring assays will often use one of the following scientific techniques to determine viral 
load. These techniques include either; enzyme-linked immunosorbent assay (ELISA), PCR or flow 
cytometry10. These techniques are mostly utilized within developed settings and are often modified for 
specific usage in developing settings. The next section describes these techniques with both their 
advantages and disadvantages. 
 
1.3.1.  ELISA  
 
ELISA is a method typically used to detect antibodies against HIV-1. ELISAs are the most widely 
applied tests in immunodiagnostics. Commercial ELISA kits are used as the initial HIV-1 screening 
assay when an individual is being tested for the presence of HIV-166. The principle of ELISA is 
illustrated in Figure 10. It is based on the interaction between the viral antigens and the antibodies that 
the patient’s immune system has produced in response to the presence of HIV-1. The main reason why 
ELISA is the most widely applied assay for initial HIV-1 screening is due to its simplicity67. 
 
 
Figure 10: A schematic representation of an antibody capture ELISA principle used to capture HIV-
167. Viral antigens are immobilized to matrix, capturing any antigen specific antibodies within the 
patient’s sample. Thereafter, detection antibodies are flown through the system, binding to any captured 
antigen specific antibodies. The detection antibodies produce a signal which can be detected as either a 
positive or a negative result.   
 
 
The advantages ELISAs include, high sensitivity (>99.5%), high specificity and amenability with 
automation, therefore ease of use67. However, ELISA assays do have some drawbacks that may limit 
their widespread use. These drawbacks include, costly and sometimes unaffordable reagents and cross-
reactivity with non-viral protein targets which may cause variability in the results. Other limitations 
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include that the test only provides qualitative results, thus rendering it unsuitable for viral load 
monitoring66,67. Furthermore, the ELISA reader machine itself is very expensive and estimated to cost 
US$ 9 500 (ZAR 152,429.0). As a result tests are generally not being performed at the point-of-care 
setting due to the unavailability of the ELISA reader at most clinics. To circumvent this problem, 
patients’ samples are often sent for analysis at specialized laboratories. For example, in South Africa, 
ELISA tests for rural clinics are commonly carried out by the South African Medical Research Institute 
(SAMRI). This means that patient samples are sent to the institute, resulting in up to a weeklong lag 
until the results are sent back to the clinic68. This process creates difficulties in following up with 
patients68. Despite these disadvantages, ELISA assays have still managed to maintain popularity. This 
is primarily due to them being a relatively cost-effective screening tool compared to most alternatives. 
ELISA as a screening tool costs (ZAR 126)70 per patient, per assay in South Africa.  
 
1.3.2.  Polymerase Chain Reaction 
 
PCR has emerged as one of the most powerful tools for the amplification of genes or their RNA 
transcripts66. PCR is carried out in a machine known as a thermal cycler. The thermal cycler contains a 
thermal block with holes, into which a 96-well plate (containing all PCR reagents) is placed upon. 
Within the machine, the temperature is raised and lowered at specific times throughout the PCR cycle71. 
Each PCR cycle has three steps per 1 cycle. Each cycle includes the following steps; denaturation, 










Figure 11: Schematic representation of the PCR Principle71. A specific DNA target will repeatedly 
undergo many PCR cycles, each involving denaturation, annealing and extension. These cycles produce 





The first step within the PCR cycler is a denaturation step which involves the double stranded cDNA 
being separated by heating the solution above the DNA’s melting temperature71. The thermal cycler is 
then cooled to a temperature that allows for specific primers to bind to the target DNA in a process 
known as annealing. The temperature is then raised again to allow the polymerase enzyme to extend 
the primers (extension phase) by adding the nucleotides in order to create the developing DNA strand71. 
 
The standard of care for monitoring a patient who is on HAART involves quantitative viral load testing 
based on plasma HIV-1 RNA concentrations. The favoured method for monitoring HIV-1 patients once 
they have been placed onto HAART is RT-qPCR viral load testing61. RT-qPCR measurements enable 
care providers to determine whether patients have a high or low level of HIV-1 circulating in their 
bloodstream. A high level of HIV-1 circulating in the bloodstream is an indication that the virus is 
actively replicating and the treatment regime is no longer effective61. RT-qPCR is a technique that is 
commonly used to detect RNA expression. It is used to qualitatively and quantitatively detect gene 
expression through creation of complementary DNA (cDNA) transcripts from the HIV-1 RNA using 
fluorescent probes, such as Taqman probes72. The use of these fluorescent probes is what allows RT-
qPCR to measure amplification as it occurs during the experiment. As it can be seen in Figure 12, RT-
qPCR is utilized to clone expressed genes by reverse transcribing the HIV-1 RNA, released by HIV-1 
virus into the CD4+ cells, into cDNA through the use of the RT enzyme. This creates newly synthesized 









Figure 12: Schematic diagram of the RT-PCR principle72. HIV-1 RNA is reverse transcribed to cDNA 
via the reverse transcriptase enzyme. This produces newly synthesized cDNA, which can then be 





RT-qPCR is characterized by the point in time during the cycle when the amplification of a PCR product 
is first detected. The higher the starting copy number of the sample, the sooner the fluorescent signal is 
detected. Each PCR assay requires the DNA sample, DNA polymerase and primers that detect and bind 
to the sample. Also required are four base deoxynucleotides including adenine, guanine, cytosine and 
thymine, which are the building blocks used by the polymerase enzyme to create the PCR products71. 
These components, including reverse transcriptase are mixed into a 96-well plate and placed in the 
thermal cycler. 
 
The approach of PCR is a very important process that monitors a patient’s responsiveness to HAART 
therapy with many advantages that include73; rapid production of results, high sensitivity and high 
specificity of 97-98%. The Amplicor HIV-1 monitor Test 1.5 is an HIV-1 RNA PCR test which has a 
lower detection limit of 400 copies/mL and an upper limit of detection of 10,000,00074. If a patient’s 
viral load is below the level of detection, an “undetectable” result is reported, meaning the assay was 
not sensitive enough to be able to detect the virus74. The use of PCR also has the ability to produce 
billions of copies of a specific product and the ability to quantify the amount of product synthesized in 
order to monitor disease progression. Lastly, there should be relatively low start-up costs for equipment 
as most laboratories have the necessary equipment for performing PCR assays. As with every technique, 
there are disadvantages which include; high sensitivity that implies vulnerability to any form of 
contamination. This could yield misleading results. Furthermore, designing of primers for PCR which 
requires prior knowledge of the sequence of the target DNA. This knowledge is essential to prevent 
non-specific annealing of primers to sequences that are similar, but not completely identical to the target 
sequence1,14. There is also a possibility of incorrect nucleotides being incorporated into the PCR 
sequence by the polymerase enzyme. The RT-qPCR process requires a suitable detection chemistry in 
order to report the presence of PCR products. The instrument needs appropriate software for real time 
quantitative analysis of the amplification process. Reagents are expensive and the overall assay requires 
trained technicians. Furthermore, the entire PCR process is time consuming with certain PCR steps 
requiring dedicated laboratory space in a sterile laboratory space1,14.  
 
1.3.3.  Flow Cytometry 
 
CD4+ count through flow cytometry is considered an essential part of HIV-1 care. CD4+ cell count 
analysis has been described as the best surrogate marker in comparison to viral load assays49, see 
previous figures, Figures 8 and 9. A CD4+ cell count can be used to monitor a patient’s immune system 
in order to assess if HAART treatment needs to be initiated or if HAART treatment is effective for the 
patient75. If the CD4+ cell count continues to decrease, it means treatment is failing and the patient 
needs to be placed on new therapy. On the other hand, if a patient’s CD4+ count begins to increase in 
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numbers, this is an indication that the treatment regime is successful. Therefore, even though this 
method is not a viral load assay in the sense that it is not measuring virions or RNA in the patient’s 
plasma, it is discussed here given that it is used in certain areas, when viral load assays cannot be 
performed. 
 
Flow cytometry has been termed the gatekeeper for assessing the immune status and establishing 
eligibility for treatment and care due to its ability to provide rapid analysis and ability to quantitatively 
measure the number of CD4+ cells a patient has76. As HIV-1 progresses, the number of total CD4+ cells 
decreases, allowing the absolute number of CD4+ cells to provide a powerful laboratory measurement 
for predicting, staging and monitoring progression as well as a patients response to HIV-1 treatment77. 
Unfortunately, the reality is that resource-limited countries lack the facilities to measure CD4+ counts, 
which stands in sharp contrast to the urgent need for implementing effective ART in these countries78.  
   
A flow cytometer is used to perform flow cytometry and consists of four basic components. The four 
components include laser(s), a fluidic system, optics and electronics (or an external computer system) 
and measures fluorescence and optical characteristics of cells, depending on the angle of light 
scattered77. When fluorescently labelled CD4+ cells pass by the light source, the fluorescent molecules 
are excited to a higher energy state and when they return to their resting state, the fluorochrome emits 
light energy at a higher wavelength. The measurement of this higher wavelength is analysed to provide 
a count of the number of CD4+ cells present in the sample77. The flow cytometry process requires 
multiple steps79, as seen in Figure 13. In principle, CD4+ cells in the patient’s sample are labelled with 
fluorescent detection antibodies. The sample is then loaded into the collection stage of the flow 
cytometer, drawn up into the fluidic system and then pumped into the flow chamber. Within the flow 
chamber, the CD4+ cells are combined with sheath fluid and passed through a laser beam which shines 
and excites the cells as they flow through. This excitation results in an emitted fluorescence, which is 
converted into an electrical signal via photodetectors and analysed by an external computer. The 
information is then displayed as a scatter plot (Figure 16) and quantitatively analysed to determine the 














Figure 13: Schematic representation of a flow cytometer77. A patients CD4+ cells are labelled with 
fluorescent detection antibodies. The sample is then loaded onto the collection stage of the flow 
cytometer, drawn up into the fluidic system and pumped into the flow chamber. The CD4+ cells are 
then combined with sheath fluid and passed through the argon-ion laser, exciting the CD4+ cells as they 
flow through. The excitation of the cells results in an emitted fluorescence, which is converted into an 










Figure 14: Scatter plot of CD4+ cell count found in a total lymphocyte population79. Labelled CD4+ 
cells emit a fluorescence as they pass through the argon-ion laser within the flow cytometer. This 





Flow cytometry has remained one of the most popular tests to evaluate CD4+ cell counts due to the 
following advantages; the assay is extremely quick and thousands of cells are counted in seconds 
compared to 250 cells per minute counted by a scientist using a hemocytometer. The assay also  
provides quantitative and qualitative information77,11. Flow cytometry does have some limitations which 
include79, the high cost of the actual machine, which second hand can cost approximately US$ 30 000 
(ZAR 477,447) and brand new can cost as much as US$ 300 000 (ZAR 4,774,470). Flow cytometers 
are extremely large in size, taking up a lot of space, and a well-trained personnel is required to operate 
the flow cytometer. There are additional operational costs for the sheath fluid, servicing of machine, 
fluorochromes and analysis software that may make flow cytometry an even more expensive assay. 
However, flow cytometers are not used as initial screening tests due to being overall more costly to 
run77 and a standard CD4+ test costs US$ 38 (ZAR 576) up to US$ 67 (ZAR 1,015)80. 
 
Given the availability of multiple techniques, which ones are used in developed settings and which are 
used or modified in developing settings? The factors needing to be taken into consideration are 
resources, both financial and structural, time and labour intensiveness of the technique and assay. 
 
1.4. Review of Current HIV-1 Viral Load Assays for Developed Countries  
 
Commercial RNA viral load assays (PCR) have been widely used as the “gold standard” to quantify 
HIV-1 RNA in plasma in developed settings. Companies such as Roche and Abbott have developed 
HIV-1 viral load assays. These companies have adapted real-time technology based on fluorescence in 
or to achieve simultaneous amplification and detection, instead of just an end-point detection result2. 
The real-time technology approach offers more accurate quantification, wider dynamic range and a high 
throughput. Roche and Abbott have further included automated sample preparation to prevent carry-
over contamination and reduce manual time.  
 
The device, COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, Food and Drug Administration 
(FDA) approved, produced by Roche is an example of a PCR product utilized in developed settings. 
Within this system, an extremely conserved region within the Gag gene is first transcribed into cDNA 
by the RT enzyme and then amplified during PCR2. During the amplification step, the use of TaqMan 
probes enables real-time detection. The Taqman probe is a dual-labelled sequence of DNA that is 25-
30 nucleotides in length. There is a fluorescent reporter (Taqman) at the 5ʹ end and a quencher at the 3ʹ 
end. Due to the Taqman probe and quenchers close proximity, the Taqman probes fluorescence emitted 
is negatively suppressed by the quencher. During the amplification step, Taq DNA polymerase 
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elongates the forward primer and cleaves the TaqMan probe, which then hybridizes to the amplified 
HIV-1 cDNA2. When the TaqMan probe is cleaved, the distance between the quencher and the TaqMan 
probe is increased, resulting in detectable fluorescence emission, see Figure 15A. When the 
fluorescence intensity exceeds the background signal, the cycle number of PCR at this point is recorded 
and utilized for quantification. The cycle number is compared to a standard curve, whereby the HIV-1 
RNA viral load is extrapolated from the cycle number (Figure 15 B and C)81. This assay is capable of 
detecting and quantifying a viral load range from 48 – 107 copies/mL as well as detecting HIV-1 




















Figure 15: A) Principle of the TaqMan (reporter) probe. Due to the TaqMan probe and quenchers close 
proximity, the TaqMan probes fluorescence emitted is negatively suppressed by the quencher. During 
the amplification step, Taq DNA polymerase elongates the forward primer and cleaves the TaqMan 
probe, which then hybridizes to the amplified HIV-1 cDNA. When the TaqMan probe is cleaved, the 
distance between the quencher and the TaqMan probe is increased, resulting in detectable fluorescence 
emission2. B) Due to the TaqMan probe, real-time monitoring during the PCR amplification can occur. 
When the fluorescence intensity exceeds the background signal, the cycle number of PCR at this point 
is recorded and utilized for quantification2. C) Standard Curve for quantification. The cycle number is 






Another FDA approved assay, similar to COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, is the 
RealTime HIV-1 assay produced by Abbott2. Within this assay, HIV-1 RNA undergoes RT and is then 
quantified by PCR. However, the difference between RealTime HIV-1 assay and COBAS® is that 
RealTime HIV-1 targets a highly conserved integrase gene within pol, unlike COBAS® which targets 
gag. The RealTime assay has a much wider subtype coverage including A-D, F-H and groups N and O, 
which are not detected by COBAS® 2. 
 
1.5. Alternative HIV-1 Screening methods and approaches in Resource-Constrained 
Settings 
 
The previous section discussed the current viral load detection and monitoring methods that are widely 
used in developed settings with well-funded laboratories. These methods require finances, a high level 
of expertise to perform the tests and interpret data, equipment, laboratory space and adequate 
infrastructure66. These requirements are abundantly available in developed countries and as a result, 
their HIV-1 treatment approach involves routine use of viral load measurements and CD4+ cell counts82. 
However, these monitoring methods are difficult to adapt in resourced-constrained regions, where there 
are limited resources and multiple challenges. Firstly, viral load monitoring is only available in 
reference laboratories, where they are financially supported by national and international efforts2. 
Secondly, the provincial hospitals and local clinics both lack basic laboratory infrastructure including 
reliable power and water supply, refrigeration and air conditioning2. Without stable electricity, it is 
impractical to maintain air conditioning and a temperature-controlled environment necessary for long 
term storage of patient samples and reagents82. Thirdly, technicians and staff members in such clinics 
and hospitals are rarely trained to perform technologically complex molecular techniques2 or to even 
operate and maintain equipment82. Therefore, robust equipment and methods are needed to be able to 
withstand harsh conditions in the rural clinics. However, most often, viral load measurement machinery 
is completely absent from routine equipment lists due to the challenge of running, setting up and 
servicing them82. Lastly, fluctuations of environmental humidity and temperature cannot be controlled 
during transportation and storage of samples2. 
 
There are a few strategies and less expensive monitoring tools that have been developed for resource-
constrained areas. Strategies employed include, DBS and sample pooling. Less expensive monitoring 
tools developed and utilized include; Cavidi ExaVir™ RT assay, PerkinElmer Ultrasensitive p24 assay 







DBS is a technique that has gained popularity in rural clinics as it does not require electricity or 
specialized equipment for long term storage of samples10. DBS does not need cold-chain transport of 
liquid plasma samples, which would be far too costly and logistically complicated to perform for rural 
areas10. DBS involves sending patient’s samples elsewhere for testing by PCR, which unfortunately has 
a slow turnaround time from sample–to-answer of up to several weeks2. This can lead to high loss-to-
follow up.  Briefly, performing a DBS involves a single drop of a patient’s blood being placed on filter 
paper. Once the blood has dried (4 hours), the card is packaged and sent at ambient temperature to 
another laboratory. This DBS is then analysed83 via RT-qPCR, providing an HIV-1 viral load10. A study 
done by Nishaki Mehta et al.,2009; performed on DBS samples using a real-time LightCycler (rtLC) 
PCR assay was costed at US$ 4.55 (ZAR 34)84. Within the study, 50 µl of whole blood was spotted 
onto filter paper, the filter paper was then allowed to dry for a minimum of 3 hours at room temperature 
and then placed within a ziplock bag with silica desiccant (reduce humidity within the bag)84. Within 
the study, DBS stored at -20°C and 37°C were analysed and it was shown that there was no statistically 
significant difference in viral load for those samples stored at -20°C and 37°C84. However, besides the 
cost of taking the sample and placing it onto a card, the cost of transport to send the sample to the 
relevant laboratory needs to be taken into account, therefore the cost per test will be higher taking 
transport into consideration.  
 
1.5.2. Viral Load Pooling 
 
A second strategy employed by resource-limited settings includes viral load sample pooling. This 
strategy is a very common practice in order to cut costs within these regions11. It involves mixing 
together up to 5 patients’ blood samples and testing them as one sample via RT-PCR. If the combined 
average viral load of the pooled specimen is above 1000 copies/mL, it is concluded that HAART 
treatment is failing for a particular patient. It is only after this observation when each patient within that 
sample pool will be tested individually in order to identify the patient whose treatment is failing44. This 
method has the advantage of being both time and cost-effective9, reducing costs of screening to up to 
70% compared to individually testing patient samples85. 
 
The inexpensive alternative monitoring tools developed for viral load monitoring in resource-limited 
settings include; Cavidi ExaVir™ RT assay, PerkinElmer Ultrasensitive p24 assay and lastly, in-house 
RT-qPCR assays2. The ExaVir™ RT assay and PerkinElmer Ultrasensitive p24 assay are both based 
on an ELISA principle, whereby the activity of RT and the level of p24 antigen are measured. In-house 
RT-qPCR utilizes the same TaqMan technology as described by Roche, however this method targets 
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another highly conserved region within the long terminal repeat (LTR) of HIV-12. These alternative 
techniques have significantly reduced cost US$ 13 - US$ 20 (ZAR 201–ZAR 310), compared to the 
commercial viral load assays US$ 50 – US$ 100 (ZAR 776-ZAR 1,552). In addition, the Ultrasensitive 
p24 assay and the ExaVir™ assay are both technologically simpler compared to commercial RNA viral 
load assays and therefore do not need highly skilled operators2. However, both these assays are still 
time-consuming and labour-intensive. The in-house RT-qPCR method, although highly correlated with 
commercial viral load assays, still require expensive thermal cyclers and trained operators, which 
hinders their use in de-centralized laboratories and clinics2. 
 
1.5.3. Cavidi ExaVir™ RT Assay 
 
This assay is an ELISA-based assay measures the activity of the RT enzyme. Briefly, the first step 
within this assay is the separation part of the plasma. During this step, the plasma is treated to inactivate 
cellular enzymes86. From here, HIV-1 virions are purified from the plasma by the use of a gel which 
binds the virions. All antibodies and ART drugs are washed away during this stage86. Purified HIV-1 
virions are then lysed to release RT. The second step is the RT-assay. During this stage, the released 
RT is analysed in an ELISA set-up. An RNA template is bound to the bottom of a 96-well RT reaction 
plate. A reaction mixture, containing primers and RT substrates are added to the plate with the lysate 
(lysed HIV-1 virions). If there is RT within the lysate, the enzyme will synthesise a DNA-strand from 
the bound RNA template within the well86. After incubation at 33°C for 40 hours, the synthesis of a 
DNA-strand is detected by the addition of an alkaline phosphatase (AP) – conjugated anti-BrdU 
antibody and a colorimetric AP substrate. The colour intensity correlates with the RT activity. Unknown 
samples are compared to known standards2. The ExaVir™ version 3.0, has a low detection limit of 200 
RNA copies/mL, increased throughput (180 samples per week per operator) and shortened turnaround 
time (48-72h). More importantly, the cost of this assay can be reduced to US$ 13.66 (ZAR 213) per 
test2.   
 
1.5.4. PerkinElmer Ultrasensitive p24Assay 
 
The PerkinElmer Ultrasensitive p24 assay is another ELISA based method, whereby the level of HIV-
1 p24 antigen is measured. HIV-1 p24 antigen has a strong correlation with HIV-1 RNA levels (Figure 
7).  Firstly, specimens are lysed by the kit buffer and incubated at 100 °C for 5 minutes to release p24 
molecules to a maximum degree from HIV-1 virions2. Next, the lysate is added to specific capture 
antibody-coated 96-well plate and p24 antigen are captured by the capture antibodies. Captured p24 
antigen is recognized by a biotinylated anti-p24 antibody, which is followed by the colorimetric 
detection via streptavidin-horseradish peroxidase conjugate2. Emitted colour intensity of a sample is 
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compared to intensities emitted from known standards of known concentrations2. However, despite this 
assay showing good correlation with commercial RNA assays in some settings, there has been 
discordant results observed in some studies. For example, this assay detected 66.7% of the specimens 
with a viral load less than 10 000 copies/mL, but 87% detection with a viral load of between 10 000 
and 100 000 copies/mL2. This assay can also not reflect the response to ART well as nucleic acid viral 
load assays, therefore further improvement and evaluation are needed so that this assay can be used for 
viral load monitoring in resource-limited settings2. 
 
1.5.5. In-House RT-PCR Assay 
 
RT-qPCR are commonly used in commercial viral load assays, but recently the development of low-
cost in-house RT-qPCR for HIV-1 RNA quantification has come about. This assay targets a highly 
sequence-conserved region within HIV-1, LTR2. This allows greater subtype coverage, which is more 
diverse in resource-limited setting compared to developed countries. By utilizing a probe that is a 
shorter minor groove binding probe and a shorter forward primer, viral load values obtained by this 
assay were highly correlated to values obtained by Roche assays2. In-house RT-qPCR is able to detect 
Group N and O, which are not detected by some Roche assays. The major benefit of this new approach, 
is the cost. The cost to perform this assay has been lowered to US$ 20 (ZAR 313) 2. However, despite 
the cost per assay being significantly reduced, this assay still requires high-cost equipment, good 
laboratory infrastructure and well-trained technicians, restricting its use in district laboratories and rural 
clinics2. 
 
Although these inexpensive alternative viral load assays can be performed at centralized laboratories, 
it would still be very difficult to implement within rural areas. Despite the reduction in cost per assay, 
the limitations for the need of basic instruments such as 96-well plate washers, a reader for the RT assay 
and well-trained technicians still prevent theses assays being used in resource-limited settings. This is 
why often strategies such as DBS and sample pooling are resorted to, in order to further cope with these 
limitations, as it may still be a more cost effective approach. Ideally, portable, instrument-free systems 
that can be used by health care workers with minimal training and that can provide a readout in 30 
minutes or less would be preferred2. Such a system would facilitate clinical decisions whilst patients 
are on site. Such an approach is known as point-of-care testing (POCT). POCT is a strategy whereby 
testing is performed near to or at the site of patient care, where the results may lead to an immediate 
change to the patients ART regime76. HIV-1 POC viral load assays need to be performed using a low-
cost disposable device, less than US$ 10 (ZAR 156). This is feasible due to the small consumption of 
reagents in the miniaturized system.  Due to the low cost, the self-contained device with preloaded 




To address current viral load challenges for resource-limited settings, new approaches based on 
microfluidics, have been developed towards viral detection in a POC testing format. A microfluidic 
POC device approach contains the following characteristics, low cost, short turnaround time, high 
sensitivity and simple procedure. This device can also be easily run by less-trained health care workers 
at the POC setting.  
 
1.6. Microfluidic Technology 
 
Microfluidics is the science and technology of systems which process or manipulate small amounts of 
fluids (10-9 – 10-18 litres), using channels with dimensions of tens to hundreds of micrometres87. The 
diameter of these channels are about the thickness of a human hair.  
 
Microfluidic large scale integration (LSI) arose in 1993 and describes a microfluidic channel circuitry 
composed of chip-integrated microvalves. These microvalves are based on flexible membranes between 
two layers, a liquid guiding layer and a pneumatic control-channel layer88. The microvalves close or 
open in correspondence to the pneumatic pressure that is applied to the control-channels. By combining 
multiple microvalves, features such as micropumps and mixers can be incorporated within the device88. 
During the same time microfluidic LSI arose, a novel fabrication technology for microfluidic channels, 
called soft lithography made its appearance88. Soft lithography describes a set of techniques for 
fabricating microstructures in an elastomeric material89, such as PDMS, and uses replica molding of the 
elastomeric material to fabricate stamps as well as microfluidic channels90. Advantages of soft 
lithography, include the ease of fabrication, rapid prototyping and biocompatibility90. Microfluidic 
devices are typically created using multilayer soft lithography (MSL), which is the combination of 
multiple layers of soft elastomeric material made via the process of soft lithography and bonded 
together91. The most common materials for the fabrication of microfluidic devices during soft 
lithography includes, poly-dimethyl siloxane (PDMS) and silicon. In this dissertation, PDMS device 
fabrication using a method known as multilayer soft lithography (MSL) will be focused on, see 
Appendix A for MSL method. The manufacturing of microfluidic PDMS chips consist of three 
processes. These first process involves, creating the device using a computer-aided design (CAD) 
program (AutoCAD in particular), followed by photolithography and the last process is, MSL. 
 
1.7. Microfluidic Fabrication Process  
 
The first process to construct a microfluidic device is designing the device on AutoCAD. Once this is 
completed, the design is printed onto a high-resolution transparency with 40 000 dots per inch (DPI). 
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Once this transparency has been printed, it now serves as a photomask in the process of 
photolithography92. 
 
Photolithography refers to the use of light to create a pattern onto a silicon wafer using a photo-reactive 
material (photoresist)93,. At the end of the photolithography process, the resultant patterned silicon 
wafer is known as the master mold. This master mold is used as the template for MSL see Figure 18 for 















Figure 16: Steps of a typical photolithography process for the development of a patterned silicon wafer. 
The process starts with the preparation of the silicon wafer by a dehydration bake. Next, photoresist is 
coated onto the wafer via spin coating. The wafer is then baked to remove any excess photoresist 
solvent. Once the wafer has dried, it is aligned and exposed by UV light. From exposure, a post-
exposure bake is completed which is then followed by the development of the pattern that has been 
transferred to the wafer. The final step involves stripping. This removes the remaining photoresist on 
the wafer by using a phenol – based organic solvent94.  
 
 
Briefly, the typical process of photolithography involves the following steps; firstly, silicon wafers are 
preparation by dehydration baking and coating of photoresist onto the wafer. This is done by pouring 
photoresist onto the wafer and spin coating94. This is then followed by a prebake, which removes excess 
photoresist solvent. Once the wafer has dried, it is aligned with the photomask on a mask aligner and 
exposed by using UV light in the range of 350 – 450 nanometer (nm). This exposure causes the transfer 
of the pattern on the photomask onto the wafer. After exposure, a post-exposure bake is completed 




commonly used solutions in the development process are aqueous bases developers94. Development is 
one of the most critical steps in the photoresist process as it determines the shape of the photoresist 
profile. The development process removes any photoresist that was not exposed to the pattern, creating 
etches within the wafer.  Once the development solution has been applied for a certain time (subject to 
design) it has to be rinsed off in order to stop the development process94. The final step in 
photolithography involves stripping, a process which removes the remaining photoresist on the wafer 
by using a phenol – based organic solvent94. 
 
Once the process of photolithography is completed, the master mold now serves as the mold for casting 
PDMS patterns in the soft lithography process and subsequently the construction of a microfluidic 
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Figure 17: Principle of MSL. A) PDMS is poured onto the control layer master mold, cured and then 
peeled off. B) PDMS is poured onto the flow layer master mold, cured and then peeled off. C) The 
control layer and flow layer are aligned together. D) Once the two layers are aligned, they are baked 
together creating an irreversible bond90.  
 
 
The process of MSL for the dissertation can be found in more detail in Appendix A. Briefly, all molds 
are primed using TMCS vapour. Next, PDMS is mixed and poured onto the control layer mold. The 
flow layer was then made by mixing PDMS together. Once mixed, the mixture was poured onto the 
flow layer mold and spun at 1800g. Both the thick layer and flow layer molds were placed into a 
convection oven and baked. Once baked, the thick layer was peeled from the mold and. aligned onto 
the flow layer mold, aligning all valves. Once aligned, it was baked in the oven to bond the two layers 
together. Once baked, the bonded layer was peeled off from the mold.  
 
1.8. Advantages and Limitations of Microfluidics 
 
Microfluidics has the potential to become a global resource both in biological and medical science for 
a variety of reasons. These include high throughput processing as well as low reagent consumption 
(economy of scale). Economy of scale is achieved by carrying out reactions on microfluidic devices 
with length scales ranging from tens to hundreds of microns, resulting in up to six orders of magnitude 
smaller volume than is possible with the current standard HIV-1 viral load assays95. It is due to these 
small volumes and length scales that many hundreds to thousands of microfluidic assays can be 
performed simultaneously on a single device taking up a few centimetres. By combining both low 
reagent volumes and small length of scale, this reduces the cost per assay96. Other advantages include, 
complex fluidic manipulations, such as metering and mixing which can be performed on chip, making 
it possible to scale down current bench-top assays97. Lastly, another key advantage lies in the PDMS 
material itself. PDMS is an inexpensive material that offers several advantages such as being a rubber-
like elastomer that has good optical transparency and biocompatibility88. With these aforementioned 
advantages, microfluidics aims at overcoming the current technological burden that the world is facing. 
One main advantage of microfluidics includes the ability for the chip to be redesigned on AutoCAD. 
This enables the device to house multiple patient runs on one chip. A chip design could easily be made 
to have 100 or 1000 reactors, meaning 100 - 1000 patient samples could be processed and analysed via 
automation simultaneously. The cost-effectiveness of microfluidics can be seen in the long run, once 
the system has been established. With both low reagent usage and the possibility of high number of 
patient samples being processed simultaneously, the cost per assay reduces. The ability for 
microfluidics platforms to accomplish all assay steps such as sample pre-treatment and detection on a 
single easy-to-use platform, via accurate and automatic means makes them an ideal future diagnostic 
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tool to provide real clinical value for HIV-1 monitoring in low-resource, laboratory free-settings98. 
However, like most technology, microfluidics possesses certain limitations. Limitations of the platform 
mainly relate to the properties of PDMS, for example, chemicals which the elastomer is not inert to 
cannot be processed88. PDMS also shrinks by 1% during curing and the cured PDMS can also swell 
when introduced to certain solvents99. Increased temperatures is not feasible for the PDMS chip as this 
results in the PDMS chip expanding. The softness of the PDMS elastomer limits the aspect ratio (height, 
length and width) of microstructures in PDMS. If the aspect ratio of the height and length are too high 
or too low, this causes the microstructures in PDMS to deform, generating defects in the resulting 
pattern. Other limitations include; for now, difficulties in implementing microfluidic technology in the 
field of POC, as hand-held devices are required. Lastly, external components such as pressure sources 
and valves would have to be downsized, which is technically feasible, but the costs would be high88. 
Microfluidics, as most technology requires an initial start-up cost. A microfluidics system requires a 
microscope, pressurized control board and computer system. The ongoing operation of microfluidics 
itself requires tygon tubing, Eppendorf tubes, the microfluidic chip itself and the necessary reagents.  
 
1.9. Current Applications of Microfluidic Technology 
 
Presently there are a number of microfluidic applications underlying current technology. The most 
abundant application that uses microfluidics, are rapid lateral flow immunoassays, often termed as rapid 
diagnostic test (RDT). The most familiar RDT is the home pregnancy test strip and for HIV-1 screening, 
the OraQuick Rapid HIV-1/2 Antibody Test has been rated highly by the WHO due to its 100% 
sensitivity and 100% specificity when utilized in southern Africa100. 
 
 Another example of a well-known device that utilizes microfluidics, is the GeneXpert. These 
applications and assays will be discussed in more detail below. 
 
Rapid Lateral Flow Immunoassays  
 
The first RDTs, with principles of latex agglutination (a diagnostic to detect antibody using latex 
particles such as polystyrene), were developed in the 1950’s and 1960’s101. Today, RDTs for infectious 
diseases are supplied by more than 200 manufacturers worldwide as cards, strip tests or pads, and are 
usually easy-to-use and inexpensive, US$ 1 (ZAR 15) to US$ 10 (ZAR 158). In global health, the RDT 
HIV-1 antibody test are the most widely used, each being performed at least 100 million times per year 
worldwide101. 
 
The basic principle of lateral flow tests is capillary action88. Capillary action is when liquid moves along 
the surface of a solid, due to the attraction of the liquid’s molecules to the surface of the solid. This in 
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turn causes the liquid to move up, down or across the solid88. For example, a sample is introduced into 
a RDT device through the test inlet and transported into the conjugate pad, via capillary action.  The 
conjugate pad contains antibodies, which when the sample passes through, the antibodies are rehydrated 
and bind to the antigens in the sample. This reaction continues as the sample flows into the incubation 
and detection pad. On the test line, there is a second antibody which catches the particles coated with 
antigens, while a third type of antibody catches particles that did not bind to an analyte on the control 








Figure 18: Schematic design of a lateral flow test, A) Sample pad (sample inlet and filtering), conjugate 
pad (reactive agents and detection molecules), incubation and detection zone with test and control lines 
(analyte detection and functionality test) and final absorbent pad (liquid actuation). B) Start of assay by 
adding liquid sample. C) Antibodies conjugated to colored nanoparticles bind the antigen. D) Particles 




An example of a RDT for HIV-1 screening, is the Oraquick ADVANCE® Rapid HIV-1/2 Antibody 
Test from OraSure Technologies, Inc. The OraQuick Rapid HIV-1/2 Antibody Test is a lateral flow test 
that is used in resource-limited settings. This test is capable of utilising saliva or whole blood from a 
patient in a way that prevents or minimises stigma against the individual being tested. The OraQuick 
assay detects both HIV-1 and HIV-2 antibodies found in whole blood, oral fluid or plasma102. The 














Figure 19: Performing the OraQuick Rapid HIV-1 Antibody Test using whole blood. The OraQuick 
Rapid HIV-1 Antibody Test (Image 1), collection of specimen by touching the collection loop to the 
finger prick blood droplet (Image 2), dipping of the collection loop into the test tube (Image 3), a filled 
collection loop (Image 4), insertion of the loop and stirring of the specimen in the developer solution 
vial (Image 5) and insertion of the OraQuick device into the developer vial (Image 6). Test results must 
be read after 20 minutes but no later than 40 minutes (Image 7)102. 
 
 
The advantages of the OraQuick device includes the following102; high sensitivity (99.3%), high 
specificity (99.8%), results produced in minutes and ease of sample collection. Other advantages 
include that the test is not time consuming, labour intensive, requiring skilled technicians or specialized 
equipment103. A slight drawback of the system, using oral fluid is that oral fluid typically has a lower 
antibody concentration compared to whole blood. This is due to whole saliva containing bacterial and 
salivary proteases which may lead to degradation of the HIV-1 IgG antibodies104. Another disadvantage 
of this device is that any HIV-positive samples need to be confirmed via a second confirmatory test10 
such as a western blot. However, comparing the ELISA assay which is a two day labour intensive assay, 
the OraQuick Rapid HIV-1/2 Antibody device is a better choice as it provides results within  40 
minutes102.   
 
Other commercially available lateral flow test strips for diagnostic purposes include; Binax NOW which 
detects Malaria, Alere Determine HIV ½ Ag/Ab combo that detects AIDS and OncoE6 Cervical test, 
which detects cervical cancer. Another commercially available test includes StatusFirst CHF NT-
proBNP which detects congestive heart failure98. It is evident that lateral flow tests serve a wide field 
of applications including health biomarkers, pregnancy, heart attacks, glucose testing and infectious 





RDT technology is also one of the most simplistic and successful diagnostic testing platforms98 
available in the rural areas of developing countries. Lateral flow tests have contributed enormously to 
the identification of diseases without the need for any modern laboratory set-up98. The global growth of 
this technology is attributed to many factors. These factors include the need for early stage detection of 
diseases such as HIV-1 and the demand for screening tools for the preventative management of 
infectious diseases. Another factor is the requirement for cost-effective devices with little to no 
maintenance98. Lateral flow tests may be seen as the gold-standard microfluidic platform in terms of 
handling, cost, simplicity and robustness, but there are a few limitations. The simplicity of the test is a 
major drawback as there are a limited number of unit operations imprinted in the microfluidic channel. 
Highly precise liquid handling and metering is also extremely challenging88. Other limitations include, 
poor reproducibility, poor accuracy and low sensitivity98. Lateral flow tests are also only qualitative in 
that they provide yes or no answers. They would not be able to be suitable for viral load monitoring. 
 
Another device which uses microfluidics, is the GeneXpert MTB/RIF assay. This device is a rapid 
molecular assay that can be utilized at the point-of-care interface, requiring minimal technical expertise. 
Xpert simultaneously enables diagnosis of Mycobacterium tuberculosis (MTB) with the identification 
of rifampicin resistance within 2 hours105. Rifampicin resistance is caused by a mutation in the rpoB 
gene of MTB, therefore this resistance can be detected by identifying mutations within this region. A 
major advantage of the Xpert, is that unprocessed sputum samples can be used almost directly into the 
system. Xpert has been successful in combining both sample preparation and detection with fully-
automated RT-PCR amplification105. Within the Xpert, there is a cartridge-based system (Figure 20) 
that integrates microfluidic technology, allowing almost fully automated nucleic acid analysis105. This 
cartridge contains multiple chambers preloaded with liquid buffers and reagent beads needed for sample 
processing, DNA extraction and RT-PCR. The cartridge alone is able to purify, concentrate, detect and 


























Figure 20: A) GeneXpert MTB/RIF cartridge105. B) Inside side view of cartridge, highlighting all the 
beads that enable the assay to be carried out via automation106. 
 
 
Microfluidic approaches and applications have shown to provide key advantages over current standard 
laboratory techniques used within developed settings. So far discussed are the HIV-1 viral load assays 
in developed countries (COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test and RealTime HIV-1 
assay) and the alternative HIV-1 viral load assays for resource-limited settings (Cavidi ExaVir™ RT, 
PerkinElmer Ultrasensitive p24 and lastly, the in-house RT-qPCR assays). Unfortunately, despite the 
alternative HIV-1 assays used in resource-limited settings having reduced costs, they still are time-
consuming and labour intensive. However, with the advantages of microfluidics, there has been 
advancement in HIV-1 POC viral load assays using microfluidic technology.  
 
1.10.  Advances in Developing HIV-1 POC Viral Load Assays In Resource-Limited 
Settings. 
 
Two major microfluidic approaches that are able to quantify HIV-1 viral load or provide a surrogate for 
viral load at the POC setting include; microfluidics-based virus count and POC CD4+ cell count 
respectively.  
 
Microfluidic-based virus count 
 
More recently, HIV-1 whole virus particles have been utilized as a viral load marker, in microfluidic 
systems. Assays quantifying the HIV-1 particle, in theory, are more accurate compared to RNA viral 
load assays, because they decrease the quantification bias that arises from RNA degradation and 
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amplification inhibition in nucleic acid testing. The degradation of HIV-1 RNA is due to freeze-thaw 
cycles and ubiquitous RNases. With the progress in the area of microfluidics, direct virus counting has 
become more feasible. This can be seen in a paper by107. Within this paper, 10µl of whole blood was 
pumped into a microfluidic chamber, previously coated with anti-gp120 antibody. HIV-1 particles 
present, were captured by the anti-gp120 antibody. The captured HIV-1 particles were then sandwiched 
by a biotinylated anti-gp120 antibody that binds to a streptavidin-conjugated green quantum dot107. 
Furthermore, biotinylated ConA lectin was also added, which enabled co-recognition of captured HIV-
1 particle, due to the biotinylated ConA lectin red quantum dot binding to the streptavidin-conjugated 
green quantum dot107. HIV-1 particles were indicated by co-location of the both the green and red 
fluorescent signal. This method eliminates the process of nucleic acid isolation, potentially cutting the 
cost of one device to US$ 5 (ZAR 78) and also uses such a small volume of sample, all that is required 
is a fingerpick2. However, the disadvantage of this approach is the detection of fluorescence via 
microscopy is not practical at the POC setting. The end goal would be using a portable lensless imaging 
system2. 
 
Microfluidic POC CD4+ cell count  
 
As previously highlighted, the number of CD4+ T cells is necessary to determine the immune state of 
HIV-infected individuals and their HAART effectiveness. Functionalized microfluidic devices have 
been developed that are capable of capturing CD4+ cells from 10µl of whole blood2. In brief, anti-CD4+ 
antibodies were immobilized by biotin-streptavidin interactions on the surface of the microfluidics flow 
channel. Any present CD4+ cells in the whole blood, were captured and then tagged by a fluorescently 
labelled antibody2. The fluorescence was counted under fluorescence microscopy, which again, is not 
feasible at the POC setting. A light microscope can be used, but this would involve tedious counting 
manually. Alternative methods for CD4+ counting can be done using lensless ultra-wide-field cell array 
based shadow imaging (LUCAS), done by Ozcan and Demirci, 2008, which allowed CD4+ cell 
counting within 10 minutes using a battery-powered camera. More recently, portable cell counting 
technologies, such as the Alere Pima™ CD4 test have emerged. In 2012, the Alere Pima™ CD4 test 
made in onto the list of WHO prequalified diagnostics101. This device requires 25µl of whole blood and 
produces a CD4+ count in less than 20 minutes at the POC without a lab108. This assay requires very 
minimal time or skilled operators. Briefly, a finger prick amount of blood is collected into the Alere 
Pima™ CD4 cartridge, the cartridge is then place into the Alere Pima™ Analyser and within 20 
minutes, the number of CD4+ cells are displayed on the analysers screen108. The reaction within the 
cartridge is as follows, two specific monoclonal antibodies (CD3 and CD4) each labelled with a 
different fluorescent dye dissolve into the blood sample once the cartridge is inserted into the analyser. 


















Figure 21: The Alere Pima™ CD4 cartridge that is inserted into the Alere Pima™ CD4 analyser, with 
the reaction that occurs within the cartridge, allowing CD4 cell count. Within the cartridge, there are 
CD4 antibodies labelled green and CD3 antibodies labelled red. When both of these antibodies are co-
localized, this is denoted as a CD4 cell and is counted108.  
 
The main challenges for POC assay are to reduce overall cost, reduce sample-to-answer output time, 
requirement of instruments, reduce the need for human involvement and lastly, the assay requires high 
tolerance to variable storage conditions, whilst still maintaining high sensitivity. An assay is accepted 
for POC when it meets all the ASSURED10 criteria as well as having a detection limit of 1000-5000 
vpc/mL1. ASSURED is an acronym for affordable, sensitive, specific, user-friendly, rapid and robust, 
equipment-free and deliverable to end users10. Microfluidic devices potentially have the capability of 
being able to provide the solution to these challenges, as this technology has enabled clear progress in 
HIV diagnostics, with already commercially available microfluidics-based CD4+ cell count using a 
drop of blood from a finger prick. However, despite remarkable progress in this areas, very few 





1.11.  Dissertation Aim and Objectives 
 
1.11.1. Problem Identification 
 
Monitoring of a patient’s viral load within developing regions still to this day poses many hurdles. Most 
rural areas rely on CD4+ cell counts or sending samples to other laboratories that can perform the 
necessary assays to determine a patient’s viral load. This remains largely unaffordable due to the 
transportation costs and often leads to loss to follow up of patients due to the turnaround time of up to 
several weeks.  
 
1.11.2.  Research Aim  
 
 To design, develop and investigate the utility of an automated microfluidic device system capable of 
capturing, concentrating and quantifying whole HIV-1 particles through an ELISA approach.  
 
1.11.3. Research Objectives  
 
A) Design and create a microfluidic device. 
 
B) Automate operations of the microfluidic device, whereby the experiment would run with 
minimal human involvement.   
 
C) To test the ability of the microfluidic system to quantify whole HIV-1 virus particles.  
 
D) Create a standard curve of numerous known HIV-1 viral concentrations with resulting 














2. Materials and Methods  
 
2.1. Reagents  
 
2.1.1. Chip Fabrication 
 
Number 1 glass coverslip slides (25mm X 75mm) from Electron Microscopy Science [Hatfield, USA 
(CAT #72192-75)]; trimethylchlorosilane (TMCS) from Sigma, [St. Louis, MO, USA, (CAT# 92361)] 
and  PDMS Part A and Part B obtained from RS Hughes (Sunnyvale, CA as Momentive RTV615 Clear 
044). 
 
2.1.2. Antibodies and Antigens  
 
HIV-1 (IIIB strain) Purified Virus was obtained from Advanced Biotechnologies Inc [Progress Way, 
Eldersburg MD (CAT #10-118-000)]; NL4-3 virus was donated by Sigal laboratory (South Africa, 
KwaZulu-Natal, K-RITH); rabbit IgG antibody purchased from Cell Signalling Technology [USA 
(CAT # 2729S)] and goat IgG polyclonal-isotype control was obtained from USBiological 
[Swampscott, Massachusetts (CAT # ab37373)]. 
 
2.1.3. Fluorescent Probes and Buffers 
 
Goat anti-HIV-1 (Human Immunodeficiency Virus-1) FITC (fluorescein isothiocyanate) from 
USBiological [Swampscott, Massachusetts (CAT #H6001-10C)]; casein sodium salt from bovine milk 
obtained from Sigma Aldrich [St Louis, MO, USA (CAT#C8654-500G)]; PBS (phosphate-buffer 
saline) was obtained from Sigma [USA (CAT#P3619)] and albumin from bovine serum (BSA) from 
Sigma [South Africa (CAT#C5679-500g)]. 
 
2.1.4. gp120 Conjugated Microspheres 
 
Polystyrene goat anti-HIV-1 conjugated gp120 microsphere with a diameter of 6.1 µm were obtained 




2.1.5. Reagent Preparation  
 
The polystyrene goat anti-HIV-1 conjugated gp120 microsphere were washed multiple times with PBS 
and centrifugation, see Appendix C. 10mg/mL of BSA and casein were prepared by taking 0.1g of 
BSA/casein and mixing it into 10mL of PBS, see Appendix D. Lastly, HIV-1(IIIB) was made into 
certain stock concentrations (1x106 and 500 000 vpc/µl), see Appendix E. All fluorescent probes and 
buffers were filtered through a cellulose Acetate Membrane syringe filters, 0.20 µm – 25 mm, obtained 
from Lasec [South Africa (Lot # 14140062307)].  
 
2.1.6. Specific HIV-1 Product Information  
 
Anti-HIV-1 conjugated gp120 antibodies bound to the polystyrene microsphere were raised against 
recombinant gp120 from HIV-1 IIIB. The goat anti-HIV-1 FITC detection antibodies were generated 
in goats using a mixture of two immunogens. Lastly, HIV-IIIB was propagated in H9 cells.  
Please see Appendix B for further information. 
 
2.2. Microfluidic Device Fabrication  
 
2.2.1. Initial Stage of Microfluidic Designing 
 
The first step in the microfluidic chip design was to design the device using AutoCAD 2013 Student 
Version. Once the microfluidic design was completed on AutoCAD, the design was sent off to the 
Stanford Microfluidics Foundry at Stanford University (Stanford, California) where the master molds 
required for MLS were manufacture. Once the master molds were received, the microfluidic chips were 
fabricated. 
 
2.2.2. Chip Fabrication by MSL 
 
Molds were exposed to TMCS vapour. PDMS in 5:1 and 20:1 ratios were mixed and degassed using a 
planetary centrifugal mixer obtained from Crystal Corporation [Japan (CAT # ARE-250CE)]. The 5:1 
PDMS ratio was poured onto the control mold in a plastic Petri dish wrapped with aluminium foil 
followed by de-bubbling in the All Clear vacuum desiccator obtained from Wirsam Scientific & 
Precision Equipment [South Africa (CAT #PE/22461)]. The 20:1 ratio of PDMS was poured and spun 
over the flow mold at 1800 g for 60s using the spin processor from Laurell Technologies Corporation 
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[North Wales, U.S (CAT #WS650Mz)]. Both were baked at 80°C for 40 minutes in a Digital convection 
oven obtained from Scientific [South Africa (80L Oven Model 221)]. The control layer was peeled off 
its mold and cut into the respective chip piece. Control line ports were punched using the ACCU-
PUNCH MP 10-UNV obtained from Syneo (Texas, USA). The Control layer was then aligned on top 
of the flow layer mold under a stereoscope. The result was baked at 80°C for 40 minutes. Chip pieces 
were then cut out and peeled off the flow layer mold. Flow line ports were punched. Lastly, a dummy 
layer on a glass coverslip was created by mixing a ratio of 30:1 of PDMS. Once mixed, the mixture was 
poured onto the glass coverslip and spun at 1800g and baked in the oven. Once baked, the bonded 
control and flow chip were place onto the glass coverslip. The now assembled chip underwent a final 
bake at 80°C for 8 hours. The chip fabrication can be seen in more detail in Appendix A. 
 
2.3. Experimental Setup  
 
An inverted Olympus CKX41 microscope was equipped with an Olympus UPlanFl 100x/1.30 
numerical aperture (na) oil objective; a green (480-550 nm excitation, 590 nm emissions) and blue (460-
490 nm excitation, 520 emissions) filter set and an ultraviolet lamp from Olympus (South Africa) and 
a Nikon DS-Ri1 Colour digital camera with a 400 millisecond (ms) exposure time and a 4.0x analogue 
gain for imaging from Nikon (South Africa). We then plugged steel tubes from New England Small 
Tube (Litchfield, NH, USA) into the chip’s control channel ports. Their other ends were connected 
through Tygon® tubing from Cole-Parmer (Vernon Hills, IL, USA). This Tygon® tubing was then filled 
with deionized water, connected to Festo manifolds and operated via automation using Lab View 
software on a personal computer with a graphical user interface. When the manifold was pressurized, 
the deionized water filled the chips control lines, enabling control of the device valves.  
 
2.3.1. Testing Experimental Setup and Reagents 
 
To test both the imaging, microscope components and if the fluorescently labelled antibodies could be 
detected by the filter set within the microscope, we did the following. Firstly, the polystyrene goat anti-
HIV-1 conjugated gp120 microsphere were flown into the microfluidic device and illuminated by bright 
light (microscopes light bulb) and secondly under excitation light originating from the UV mercury 
lamp, through the appropriate filter set. Next, to determine if the FITC detection antibody could be 






2.3.2. Data Analysis of Fluorescent Microsphere Images 
 
Raw image data was analysed using Matlab R2012a Student version blob analysis, based on 
fluorescence intensity. Within microfluidics, if one reactor trapped 10 microsphere, all microspheres 
were subjected to the same experimental procedure separately, such that each microsphere is considered 
replicates of the same experiment. 
 
2.3.3. Statistical Analyses  
 
All data were expressed as mean ± standard deviation. Statistical analyses was performed on GraphPad 
Prism version 6 (GraphPad Software, San Diego, California USA). Statistical analyses of certain tests 
and conditions were performed using one-way analysis of variance (ANOVA). Values of p≤0.05 were 
considered statistically significant. P value representation provided by GraphPad Software, see Table 2 
for P value representation. 
 
 
Table 2: P value representation.   
 
 
2.4. Experimental Assays  
 
2.4.1. Photobleaching Autofluorescence 
 
The first challenge encountered was the autofluorescence of the microspheres. The presence of 
autofluorescence needed to be resolved in order to enhance the systems sensitivity in being able to 
detect the fluorescence produced by the FITC detection antibody upon HIV-1 detection. The concern 
about the auto fluorescence was that it could possibly mask any subtle or slight signal of the detection 
antibody binding to the HIV-1 virions captured on the microsphere. Osborne et al. 2000 109 stated that 
non fluorescent microspheres exhibited residual fluorescence, which could be removed via photo 
bleaching. Therefore, a polystyrene goat anti-HIV-1 conjugated gp120 microsphere was loaded into the 
Not significant (NS) P>0.05 
* P≤0.05 
** P ≤ 0.01 
*** P ≤ 0.001 
**** P ≤ 0.0001 
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microfluidic device and exposed to an excitation wavelength between 460-490 nm (Ultraviolet) for an 
extended period of time. An image was taken every 30 seconds through LabVIEW.  
 
Once this experiment had been concluded, the microspheres needed to be further investigated, which 
was not initially thought of. The next experiment to analyse the microsphere was to test if there was 
non-specific binding between the microsphere and the FITC detection antibody.  
 
2.4.2. FITC Detection Antibody and gp120 Microsphere Non-Specific Binding  
 
A microsphere, previously having been photobleached was trapping in the microfluidic chip and 
exposed to multiple 4mg/mL FITC detection antibody incubations. After each 15 minute incubation, 
the FITC detection antibody was washed away with PBS and the fluorescence signal was measured.  
 
2.4.3. Evaluating Efficient Blocking Agents   
 
The identification of non-specific binding occurring between the microsphere and the FITC detection 
antibody is important.  If a signal is detected, it should be due to the presence of the HIV-1 virions and 
not non-specific binding. The next step was to try eliminate or reduce the non-specific binding via 
testing different known blocking agents. Blocking agents are primarily utilized to prevent non-specific 
binding by taking up any available space that another reagent would bind too. In this case the FITC 
detection antibody binding to the microsphere. Different blocking agents (10mg/mL BSA, 1mg/mL 
rabbit IgG, 1mg/mL Goat IgG antibody and 10mg/mL casein) and their effect in blocking available 
binding sites on the microsphere were investigated. The first experiment conducted involved the 
recording of a microsphere’s natural auto fluorescence and subsequently, the fluorescence signal when 
the microsphere had been incubated with FITC detection antibody. Next, the blocking agents were 
tested as follows; a microsphere was incubated in the respective blocking agent for 15 minutes, next 
FITC detection antibody was incubated with the microsphere for 15 minutes and lastly, PBS was flushed 
through the channel, removing unbound FITC detection antibody, see Appendix I for further 









2.4.4. Removing Debris within the Microfluidic System 
 
Thus far during the experiments, debris was appearing within the microfluidic system. To try prevent 
the presence of debris, both the PBS and the FITC detection antibody were filtered through a cellulose 
syringe filter. The microspheres were rinsed and washed multiple times to remove any possible debris.  
 
 
2.4.5. Off-Chip Viral Stock Validation  
 
Before on chip experimentation of detecting HIV-1 virus particles, the validation of the 1x106 vpc/µl 
stock solution needed to be done. This was done as follows; Rev-CEM cells were placed at different 
dilutions into two identical well plates. 200µl of the virus NL4-3 was placed into the different Rev-
CEM cell dilutions in plate 1. 200 µl of the virus HIV-1 III B was placed into the different dilutions in 
plate 2. After a 4 day incubation at 37 ºC Cells were collected in an Eppendorf tube and spun at 3500 g 
for 5 minutes. The supernatant was removed and cells were re-suspended in 900 µl PBS and spun at 
3500 g for 5 minutes. Supernatant was removed and re-suspended in FACS buffer. Each sample was 
flown through the FACSCalibur and % infection was generated and subsequently calculations were 
done to validate the viral stock concentration, see Appendix F for further information. 
 
2.4.6. On-Chip Detection of Virus Particle Concentrations 
 
In sandwich immunoassays, a monoclonal antibody (anti-HIV-1 antibodies on the microsphere) that is 
specific to the antigen (virus particle), is bound to a surface (microspheres). Next, the sample is put in 
contact with that surface, whereby the antibody captures the antigen. Next, a labelled polyclonal 
antibody (FITC detection antibody) attaches to the captured antigen to complete the sandwich 
immunoassay. The label is a linked enzyme that creates a fluorescent signal when under UV light. The 














Figure 22: Diagram highlighting the basis behind the virus detection sandwich assay. A) In the presence 
of HIV-1, the anti-HIV-1 antibodies on the microsphere bind to the gp120 antigens of HIV-1. This 
allows for the FITC detection antibodies to bind to the microsphere - HIV-1 complex. This produces a 
fluorescence intensity which can be detected by ultraviolet (UV) light. B) In the absence of HIV-1, no 
HIV-1 binds to the anti-HIV-1 antibodies on the microsphere. This results in the FITC detection 
antibodies not being able to due to the absence of the microsphere-HIV-1 complex. No fluorescence 
intensity is produced. 
 
 
In the experiment, 10mg/mL BSA was flown through the channel from A (input) to L (output) (Figure 
23) and incubated. BSA binds to the microfluidic channel walls, reducing subsequent reagents binding 
to the microfluidic channel walls. Next, microspheres were flowed from C (input) to L (output) into the 
desired experiment channel and captured by structural sieve valves (Figure 24). Thereafter, either a 
virus particle concentration of 0 vpc/µl, 500 000 vpc/µl or 1x106 vpc/µl was flown through the channel 
from G (input) to L (output) and incubated. After incubation, any unbound virus particles were flushed 
away with PBS that flowed from D (input) to L (output). 10 mg/mL BSA was then flown through the 
system again and incubated with the microsphere-virus complex to reduce non-specific binding. PBS 
was flushed through the system to remove any unbound BSA. Next, 4 mg/mL FITC detection antibody 
was introduced from F (input) to L (output) and incubated. Lastly, PBS was flushed through the system 
to remove any unbound FITC detection antibody. A fluorescent image was then taken. A more detailed 









3. Results   
 
3.1. Initial Stage of Microfluidic Designing  
 
The first stage in creating a microfluidics device, was to design the device on AutoCAD. The result of 
this step can be seen in Figures 23 and 24, with an illustration of the device layers from a side view as 






Figure 23: AutoCAD diagram of the microfluidic chip layout, highlighting the inputs (A-H), outputs 
(I-L), control ports (green circular structures), flow layer (red), control layer (green) and a single reactor. 
The device has a push-down geometry, meaning the valves are above the flow layer, pushing down onto 
the flow layer. The control layer channels are 25 µm tall and 50 µm wide with a rectangular geometry. 
The control lines control the opening and closing of valves and sieve valves throughout the device. The 
bottom layer, flow layer (red) is a hybrid layer containing two different heights within the same layer. 
There is the height for the flow layer and a height for sections of the flow layer where the sieve valves 
Control ports (Pressurised) Input ports  
Waste ports  
A B C D 







are situated.  The flow layer contains channels that are 12 µm high and 100 µm wide with a parabolic 
cross section (rounded geometry), while the sieve valves (blue) are situated in sections of the flow layer 













Figure 24: An enlarged view of a single reactor containing sieve valves (blue rectangles), normal valves 
(green rectangles) and three individual flow channels where experiments were conducted. Sieve valves 
are actuated separately compared to normal valves, due to requiring a different threshold pressure in 
order for the sieve valves to create a narrow passage for fluids to pass through, but retaining any object 
that is larger than 5 µm in diameter. Each reactor contains three channels that can be supplied by any 





Figure 25: Illustration of the microfluidic layers that assemble to make the microfluidic chip device. 
The first layer (blue) is the glass cover slip, middle layer is the flow layer (red) and the top layer is the 
control layer (green). 
Reactor channel (Flow 
channel) 
Control channel  
Region where microspheres are 
trapped between two sieve valves 




Glass cover slip  
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3.2. Chip Fabrication by MSL 
 
From the master mold generated from the AutoCAD design, the microfluidic device was built using the 
MSL chip fabrication method (Appendix A). A photograph of the built microfluidic device can be seen 
in Figure 26.  This figure can be identically compared to the AutoCAD design as shown in Figure 23. 











Figure 26: Image of the HIV-1 microfluidic chip after chip fabrication by MSL. Inputs, waste ports, 
control ports and a single reactor have been highlighted for comparison with the AutoCAD design as 









Figure 27: Micrograph of a normal pressurised microfluidic valve versus a pressurised sieve valve. 






flow channel  
Control ports 
(Pressurised) Input ports  
Single reactor Waste ports  
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constriction of the flow channel. When a sieve valve is pressurised, any item or reagent below 5 µm 
can pass through. 
 
3.3. Automation of Microfluidic Device 
 
The graphical user interface was created, (Figure 28) allowing for the control of the microfluidic chip 
and microscope. The primary function of the LabVIEW script was to relay a recipe provided to the 
graphical user interface, prior to the start of an assay that controlled the assay. This recipe controlled 
valves, inputs, outputs, UV light, bright light and the camera. These were all controlled without human 




Figure 28: Graphical user interface for the LabVIEW program, which enabled the experiment to be 







3.4. Testing Experimental Setup and Reagents  
 
The importance of testing the biological components with the microscope components, was to verify 
that the biological components could be detected. The results were as follows.  
Microspheres were illuminated by bright light (microscopes light bulb), (Figure 29). Next, the 
microspheres were viewed under excitation light originating from the UV mercury lamp, through the 
appropriate filter set, (Figure 30). Lastly, to determine if the FITC detection antibody could be detected 
by the microscope filter cube set, the channel with the microspheres was filled with FITC detection 







Figure 29: Bright field image of three polystyrene goat anti-HIV-1 conjugated microspheres trapped 









Figure 30: Fluorescent image of the three polystyrene goat anti-HIV-1 conjugated microspheres (A-C) 
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3.5. Photobleaching Autofluorescence 
 
A microsphere was exposed to UV light for an extended period of time and as a result, the microsphere’s 
autofluorescence could be seen decreasing every 30 seconds (Figure 32). An image of the microsphere 













Figure 32: A polystyrene goat anti-HIV-1 conjugated gp120 microsphere previously incubated with 
goat anti HIV-1 FITC, being subjected to UV light over time. As it can be seen the microsphere’s 
fluorescence intensity slowly decreased over time. The fluorescence intensity eventually reaches a 















fluorescence plateau around 5500 seconds corresponding to a fluorescence intensity of 13. Each point 
seen in the graph is the fluorescence intensity at a specific time point every 30 seconds. This experiment 
was repeated 3 times and the overall trend observed was a fluorescence decrease over time, until a 











Figure 33: Images taken of a polystyrene goat anti-HIV-1 conjugated gp120 microsphere at its natural 
auto fluorescence before (A) and after UV light exposure (B). As it can be seen, the microsphere in A 
is brighter compared to B, conferring photobleaching had occurred. Within this figure, only 1 
microsphere has been shown, this experiment was carried out 3 times and all resulted in the microsphere 
losing fluorescence over time.  
 
 
3.6. FITC Detection Antibody and gp120 Conjugated Microsphere Non-Specific 
Binding 
 
The result of the microsphere previously photobleached (Figure 32) and then being exposed to multiple 
4mg/mL FITC detection antibody incubations was that at each incubation with FITC detection antibody, 
the fluorescence intensity increased, (Figure 34). This occurred despite removal of the microsphere’s 
auto fluorescence through UV photo bleaching prior and the removal of excess FITC detection antibody 
via PBS washing before each incubation cycle. Therefore, non-specific binding was occurring between 
the microsphere and the FITC detection antibody. The image of the microsphere gaining fluorescence 


















Figure 34: A graph depicting a previously photobleached microsphere having gone through multiple 
FITC detection antibody incubations. The fluorescence intensity can be seen increasing over time, per 
each incubation point, indicating that non-specific binding was occurring between the microsphere and 
the FITC detection antibodies. Here only 1 microsphere was analysed. This experiment was repeated 4 
times and all experiments showed an increase in fluorescence after each new incubations with FITC 
detection antibody. The diamond points on the graph, represent the raw fluorescence intensity values 






Figure 35: (A) Image highlighting the microspheres natural auto fluorescence and (B) the increase in 





















3.7. Evaluation of Efficient Blocking Agents  
 
The first experiment conducted involved the recording of the microsphere’s natural auto fluorescence 
and subsequently, the fluorescence signal when the microsphere had been incubated with FITC 
detection antibody, (Figure 36). Thereafter, the following experiment was conducted for every blocking 
agent. A microsphere was incubated with a specific blocking agent, rinsed and incubated with FITC 
detection antibody. The fluorescent signal was then analysed, (Figure 36). The methodology for 
different blocking agents can be seen in Appendix I. Figure 36 shows a highly significant decrease 
(p≤0.0001) in FITC detection antibody binding to the microsphere by the blocking agent BSA. There 
was a decrease from 29.8±2.387 fluorescence intensity in the control (Microsphere + FITC) to 
5.941±1.968 fluorescence intensity in the Microsphere + BSA (10mg/mL) + FITC (4mg/mL). There 
was another significant decrease (p≤0.01) in FITC detection antibody binding for the blocking agent 
rabbit IgG. A decrease from 29.8±2.387 fluorescence intensity in the control (Microsphere + FITC) to 
19.12±1.876 fluorescence intensity in the Microsphere + Rabbit IgG (1mg/mL) + FITC (4mg/mL). No 
significant change (p>0.05) was observed for the goat IgG (25.09±9.523 fluorescence intensity) and the 
casein (23.39±2.563) blocking agents. As shown in Figure 36, BSA effectively prevented non-specific 
binding the most and is the better blocking agent compared to the others. Therefore, BSA was chosen 






















Figure 36: Graph depicting the comparison between blocking agents; 10mg/mL BSA, 1mg/mL rabbit 
IgG, 1mg/mL Goat IgG antibody and 10mg/mL casein and their effectiveness in preventing 4mg/mL 
FITC detection antibody binding to the microsphere. Only BSA and rabbit IgG resulted in a significant 
decrease in FITC detection antibody binding to the microsphere ****p≤ 0.0001, and **p≤ 0.01 
respectively in comparison to the control (Microsphere + FITC). This assay was performed three times 
to validate data. The data represented in this figure, are the averages from all three repeated experiments. 
 
 
3.8. Removing Debris in the System  
 
During the running of assays within the microfluidic device, debris would come through and bind onto 
the microspheres. This caused the FITC detection antibodies to bind to the debris, leading to a false 
fluorescence increase as it created bright spots. Despite the filtering and washing of the reagents, debris 
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was still present in the microfluidic system (Figure 37). However the presence of debris did reduce 













Figure 37: (A and C) Images showing the bright field image of two microspheres with debris around 
them. (B and D) Images of the fluorescent images of (A and C) where FITC detection antibody has 
bound to the debris and caused additional fluorescence on the microsphere.  
 
 
3.9. Off-Chip Viral Stock Validation  
 
Through FACS, the viral stock of 1x106 was validated as being at that concentration. The FACS 
data showing percentage infection of REV-CEM cells at certain dilutions can be seen in Figure 



































From the percentage infection, the number of HIV-1 virus particles could be calculated: 
 
At a 1:5 dilution with a 0.54% infection 
= 0.54 x 0.25  
= 0.1325 ng/p24 
=132.5pg p24 
132.5pg p24 /µl is equal to 1x106 virus copies/µl  
 
Here it was shown that there was 1 million vpc/µl present in the 1 million vpc/µl stock made. 
See Appendix F for further information on the calculation and the protocol.  
 
3.10.  On-Chip Detection of Virus Particle Concentrations 
  
The results of testing different HIV-1 virus concentrations through the microfluidic device 
using the ELISA approach was as follows;  there was a significant increase (p≤0.01) in fluorescence 
intensity for the 1 million vpc/µl concentration (19.27±2.269) compared to 0 vpc/µl (8.226±0.599) 
fluorescence intensity. However, there was no significant increase (p> 0.05) for the 500 000 vpc/µl 
(10.06±4.252) concentration compared to 0 vpc/µl. As seen in Figure 39. 
Dilution of REV-
CEM 
% Infection Generated by the FACS 
machine 
 HIV-1 (IIIB) NL4-3 
1:5 0.54 1.24 
1:10 0.16 0.66 
1:40 0.089 0.44 
















Figure 39: Depiction of the final average fluorescence intensity for 3 repetitions of each viral 
concentration, (0 vpc/µl, 500 000 vpc/µl and 1million vpc/µl). Only 1 million vpc/µl resulted in a 
significant increase in fluorescence intensity **p≤0.01 by comparison to the control. The average 
fluorescence intensity for each of the concentrations were derived as follows; for each concentration 
the experiment was replicated a total of 3 times. Within each experiment, 3-7 microspheres were trapped 
within the channel. These individual microspheres were averaged for each of the 3 experiments. Lastly, 
the average value of each of the 3 experiments were averaged together resulting in an overall average 









4. Discussion and Conclusion 
 
HIV-1 has caused a global pandemic over the last couple of decades. There is an unmet need to 
develop POC viral load diagnostics to initiate and monitor ART  in resource-constrained settings1. The 
need for monitoring of HIV-1 and the treatment of AIDS involves consistent and regular monitoring of 
patients. This has led to the need to develop convenient and accurate methods for monitoring HIV-1 
infected individuals efficiently in resource-poor countries49. Viral load tests are often performed in 
specialized laboratories, as they require specifically dedicated materials and are mainly based on 
extremely specific RT-qPCR reactions, in order to determine viral serum concentration49. These tests 
can be difficult to conduct in developing countries where there is often a lack of resources such as funds 
and proper infrastructure to conduct specific RT-qPCR assays. However, microfluidics has recently 
emerged as an interesting field that may provide POC monitoring solutions. The goal of this dissertation 
was to design, develop and investigate the utility of an automated microfluidic device in its ability to 
capture, concentrate and quantify whole HIV-1 particles through an ELISA based approach.  
 
As seen within the results, the journey to the actual HIV-1 testing assay contained many hurdles. It was 
initially observed that the microspheres contained their own natural auto fluorescence, (Figure 30). This 
auto fluorescence was removed by photobleaching the microsphere with UV light for a prolonged 
period of time (Figure 32 and 33) as shown by Osborne et al. 2000 109. Next it was discovered that the 
FITC detection antibody was binding non-specifically to the microsphere itself (Figure 34 and 35). This 
was overcome by testing different blocking agents’ effectiveness in preventing FITC detection antibody 
binding to the microsphere. It was found that BSA was the most significant (p≤ 0.0001) in preventing 
the FITC detection antibody binding to the microsphere (Figure 36). A similar situation was seen in a 
study conducted by ShuQi Wang et al., 2012, whereby the capability of BSA to reduce non-specific 
binding of quantum dots to the microfluidic channel wall was investigated. It was found that by the use 
of BSA, the fluorescent intensity was significantly reduced, indicating that the BSA blocked binding 
sites of the channel surface, preventing the quantum dots from binding.  The next thing observed was 
debris within the microfluidic system, (Figure 37). The debris resulted in the FITC detection antibody 
binding to the microsphere. Despite efforts to filter all reagents that were placed in the microfluidic 
device, the debris presence was only slightly alleviated. The remaining presence of debris could suggest 
that the pore size of the syringe was not small enough to capture the debris. It also could suggest that 
the debris did not come from the solutions being passed through, but rather are pieces of PDMS that get 
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trapped within channels during the MSL process of chip making. The debris could possibly prevent the 
sample (HIV-1 virus particles) binding to or interacting with the microspheres anti-gp120 antibodies, 
due to being blocked by the debris. Next, before on-chip virus particle counting could be performed, 
the 1x106 vpc/µl stock solution needed to be validated so the concentrations being flowing through the 
chip were known in order to be able produce a standard curve of concentration vs fluorescence intensity. 
The 1x106 vpc/µl stock solution was validated by FACS and the on-chip viral load was able to be done.  
The microfluidic device was setup and different concentrations of HIV-1 virus particles were flown 
through. It was detected that the ELISA based microfluidics approach could significantly (p≤0.01) 
capture and detect 1 x106 vpc/µl (1x109 vpc/mL) in 3.8 hours. 
 
Over the years there have been many microfluidic systems made to quantify HIV-1 particles.  
 
In 2009, Byoung Chan Kim et al., reported direct detection of HIV-1 particles. Within the assay, broadly 
neutralizing HIV-1 gp120 monoclonal antibodies (gp120-Mabs) - conjugated magnetic beads (MBs) 
and fluorescent nanosized polymeric beads (FNBs) were used to capture HIV-1 particles within 1.5 
hours110. The HIV-1 virus particles were mixed with the conjugated magnetic beads off chip on a shaker 
for 30 minutes at room temperature. However, despite being able to detect 2x104 vpc/mL, this was 
detected off-chip via FACS. In 2010, Grace D.Chen et al., reported the concentration and purification 
of HIV-1 by microfluidic separation of superparamagnetic nanoparticles111. Firstly, HIV-1 virions were 
incubated on a rocker for 1 hour with superparamagnetic beads. Once the incubation period had been 
completed, the superparamagnetic beads were injected into the microchip. Secondly, once in the device, 
the solution was lysed and the lysate was collected for analysis via p24 ELISA off-chip. The assay had 
an 80 –fold concentration detection of HIV-1 from the initial plasma sample containing 106 vpc/mL111. 
In 2012, ShuQi Wang et al., achieved efficient on-chip isolation of HIV-subtypes. HIV-1 particles were 
captured by protein G on the microfluidic channel surface whereby anti-gp120 antibodies were 
immobilized onto112. The use of protein G made the antibody orientation perfect for HIV-1 capture. The 
captured HIV-1 particles were lysed and the lysate used for HIV-1 RNA extraction. The RNA was 
quantified using RT-qPCR. The assay as a whole could detect between 1000-10 000 vpc/mL111. Lastly, 
Hadi Shafiee et al., in 2015 fabricated flexible plastic microchips for viral load measurements in both 
plasma and saliva. They utilised electrical sensing to detect a range of 102 vpc/mL - 107 vpc/mL113. 
Through the use of biotinylated polyclonal anti-gp120 antibodies anchored to streptavidin-coated 
magnetic beads, they were able to capture HIV-1 particles. The captured particles were then lysed and 
via capacitance spectroscopy quantified on chip113. The only disadvantage within this application was 
that there were a lot of off-chip pre sample preparation. For example, the HIV-1 particles were 
introduced to the biotinylated polyclonal anti-gp120 antibodies off-chip. As it can be seen all of these 
studies employ the basic principle of ELISA to capture the whole HIV-1 virus particles, in the pursuit 
of microfluidics as an HIV-1 detection assay. However, these assays are not fully on-chip, but have a 
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lot of off-chip sample preparation, antigen capturing or detection. Such events, prevent these assays 
from being accepted as POC technology.  
 
Despite there being many POC tests available that utilise the core principle of microfluidics, there are 
none that employ the simple ELISA approach to quantify HIV-1 cost effectively, without human 
involvement and at high sample throughput. There are some devices such as the Liat HIV quant Assay, 
which utilises whole blood and can be completed within 88 minutes with a detection limit of 57 
vpc/mL10. This assay uses a similar approach to the GeneXpert MTB/RIF cartridge whereby the PCR 
reagents are within microspheres. The disadvantage of this assay however is that only one specimen 
can be sampled at a time and a technician needs to move the sample tube from the Liat tube into the 
Liat analyser114.   
 
In summary, the results provide a basic proof-of-concept that the utility of the created microfluidic 
device in conjunction with HIV-1 neutralizing antibody gp120-conjugated microspheres captured and 
concentrated 1 x106 vpc/µl (1x109 vpc/mL). This was done within 3.8 hours via complete automation 
and no pre- or post-sample treatment was done. Within this dissertation, objectives (A) design and 
create a microfluidic device in-house, (B) automate operations of the microfluidic device, whereby the 
experiment would run with minimal human involvement and (C) to test the ability of the microfluidic 
system to quantify whole HIV-1 virus particles were completed. However, due to the low limit of 
detection of the system, the final objective (D) create a standard curve of known HIV-1 viral particle 
concentrations was not able to be completed very well. The only concentrations that were able to be 
detected were, 0, 500,000 and 1,000 000 vpc/µl. The reason why objective (D) was unable to be 
completed well is due to the limit of detection of the microfluidic system. The limit of detection of this 
system was 1 x106 vpc/µl, which compared to the detection limit required for potential POC assays 
being1000-5000 vpc/mL1, this assay was not as sensitive. Comparing our microfluidics device to 
current POC applications such as Amplicor HIV-1 Monitor Test 1.5, (PCR based machine), which is 
able to detect 50 vpc/mL and above74 the microfluidic device needs to be greatly improved on.  
 
From studies cited in the literature review and discussion110,111, most current microfluidic HIV-1 
detection approaches are more sensitive and capable of detecting much lower HIV-1 particle numbers2. 
Interestingly, successful virus capture approaches have incorporated neutravidin, streptavidin and biotin 
components 113,107. There is a strong interaction between biotin and streptavidin, with a dissociation rate 
of 2.4x106 s-1115 compared to a normal rabbit monoclonal antibody which is 7x10-11 s-1116. A very 
similar approach to this dissertation’s assay was done by Kim et al., 2009; however, biotinylated anti-
gp120 capture antibodies were coated onto the neutravidin coated microfluidic channel, creating a 
strong bond. Thereafter, captured HIV-1 was co-detected by biotinylated anti-gp120 antibodies binding 
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with streptavidin conjugated green quantum dot antibodies and biotinylated ConA lectin antibodies with 
streptavidin conjugated red quantum dot antibodies. Not only does dual labelling provide a more 
reliable countable virus image, but the use of quantum dots, which provide greater photostability and 
brightness107 are said to provide a promising alternative to organic fluorophores for fluorescence-based 
biological imaging.  
 
In conclusion, the use of this in-house microfluidic device and assay approach was not sensitive enough.  
A possible hypothesis that could have occurred in this dissertations’ microfluidic system was that there 
was not a strong enough interaction between the anti-gp120 capture antibodies on the microsphere and 
the HIV-1 virus particles themselves. Thus when rinsing occurred, the HIV-1 particles were removed 
from the anti-gp120 capture antibodies. To possibly provide more sensitivity for this dissertations 
microfluidic device and future microfluidic devices, it is recommended to employ a different biological 
assay approach. For future research using an ELISA based approach for HIV-1 whole virus or particles, 
detection within a microfluidics device, researchers could look at incorporating the reaction between 
streptavidin and biotin with quantum dots for detection and also the use of broadly neutralizing 
antibodies (Bnabs). Bnabs have been said to be able to more efficiently neutralize many HIV-1 subtypes 
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Multilayer Soft Lithography Fabrication  
 
1- Priming: all molds 
TMCS vapour 3 minutes in a sealed Tupperware container. 
2- Cast Thick layer: Combine 5:1 Part A: Part B and mix in a centrifugal mixer for 10 minutes. 
Place mixture into petri dish lined with aluminium. 
3- Cast flow layer: Combine 20:1 Part A: Part B and mix in a centrifugal mixer for 10 minutes. 
4- Place mixture onto flow layer and spin at 1800 g for 1 minute.  
5- 1st Cure Thick layer: convection oven 
80 °C for 40 minutes. 
6- 1st Cure Flow layer: convection oven 
80 °C for 40 minutes. 
7- Punching push up control input holes: peel thick layer from mold. 
8- Punch control input holes. 
9- Align the thick layer onto the spin coated flow layer mold. 
10- Bake in convection oven 
80 °C for 40 minutes. 
11- Thick/flow control bonding: peel thick/flow bonded layer from mold. 
12- Punch flow input and output port holes. 
13- Cast blank glass coverslip layer: Combine 30:1 Part A: Part B and mix in a centrifugal mixer 
for 10 minutes. 
14- Place mixture on glass coverslip and spin at 1800 g for 1 minute.  
15- 1st Cure blank glass coverslip layer: convection oven 
80 °C for 40 minutes. 
16- Place thick/flow bonded layer onto cured blank glass coverslip.  
17- Ensure no air bubbles. 
18- Bake in convection oven 





Background Information on Specific Materials 
 
Polystyrene goat anti_HIV-1 conjugated gp120 microsphere 
The anti_HIV-1 conjugated gp120 antibodies bound to the polystyrene microsphere were raised against 
recombinant gp120 from HIV-1 IIIB (Subtype B, Group M). 
 
Goat anti-HIV-1 (Human Immunodeficiency Virus-1) FITC (Fluorescein isothiocyanate) 
These antibodies were generated in goats using a mixture of two immunogens, two purified virus strains, 
IIIB (Subtype B, Group M) and the Murine Norovirus.  
 
HIV-1 (IIIB strain) Purified Virus 
This virus was propagated in H9 cells and purified from culture supernatant when cells show cytopathic 
effects (cell death). The virus was then purified via the multi-step proprietary method and viral 
concentration was then determined by transmission electron microscopy (TEM), which resulted in a 
count of virus particles per mL (vpc/mL). This strain of virus corresponds to subtype B, group M. The 
















Polystyrene Goat Anti-HIV-1 Conjugated gp120 Microsphere Preparation  
 
1- 10 µl of the microsphere solution was placed into 90 µl of PBS. 
 
2- The solution was centrifuged for 5 minutes at 2500 g.  
 
3- The supernatant was removed and the pellet was re-suspended in 90 µl PBS. 
 






















10mg/mL BSA and Casein Preparation  
 
1- 0.1g of BSA/casein was weighed out.  
 
2- The weighed out BSA/casein was then placed in 10 mL of PBS.  
 






















Preparation of Viral Stock Concentrations 
 
Initial product information: HIV-1 (IIIB strain) Purified Virus 
Concentration: 6.7x1010 vpc/mL or 6.7x107 vpc/µl 
Volume: 800 µl (0.8mL) 
  
Firstly, I made a working stock of 1 million vpc/µl. From this stock I was able to use it to obtain the 
500 000 vpc/µl concentration. 
 
Volume of initial (V1) product needed =? 
Concentration of initial (C1) product = 6.7x1010 vpc/mL or 6.7x107 vpc/µl 
Volume you want to make (V2) = 1mL (1000 µl) 






C1 = 6.7x107 vpc/µl 
V2 = 1 mL (1000 µl) 













𝑉₁ = 15µ𝑙 
 
Therefore, 15 µl of 6.7x107 vpc/µl must be taken and placed into 985 µl of PBS to make a new stock 













C1 = 1x106 vpc/ µl 
V2 = 1 mL (1000 µl) 














𝑉₁ = 500 µ𝐿 
 
Therefore, 500 µl of 10x106 vpc/µl must be taken and placed into 500 µl of PBS to make a new stock 
























Information and Protocol to Validate 1 million vpc/µl Viral Stock 
. 
Information 
1- The % infection values were provided by the FACS machine. 
2- HX3B is the HIV-1(IIIB) strain and NL4-3 is a well-known and characterised lab strain, 
therefore was the control for the FACS machine.  
 
Known information to work out the number of virus copies present: 
1- 1pg p24 = 1x104 virus copies118. 
2- 1ng p24=1x107 virus copies119. 
3- 100pg p24 = 1x106 virus copies. 
4- For a 3-4% REV-CEM infection from a 1:5 dilutions is around 1ng p24. 
 
Therefore, HIV-1(IIIB) at 0.53 % infection; 
If 4 % REV-CEM infection at 1:5 dilution represents 1 ng of p24 




1- Two well plates each had Rev-CEM cells placed into the wells at the following dilutions; 1:5. 
1:10, 1:20, 1:40 and 1:125. 
 
2- 200 µl of the virus NL4-3 was placed into the different dilutions in plate 1. 
 
3- 200 µl of the virus HIV-1 III B was placed into the different dilutions in plate 2. 
 
4- 4 day incubation occurred at 37 ºC.  
 
5- Cells were collected in an Eppendorf tube and spun at 3500 g for 5 minutes. 
 
6- Supernatant was removed. 
 
7- Cells were re-suspended in 900 µl PBS and spun as in step 5. 
86 
 
8- Supernatant was removed and re-suspended in FACS buffer. 
 
9- Each sample was flown through the FACSCalibur and % infection was generated. 
 
This assay was performed in Dr Alex Sigal’s laboratory, where they had Rev-CEM cells and Nl-43 
virus already set up, so both the Rev-CEM cells and NL-43 control virus were gifts from the Sigal 
laboratory.  Rev-CEM cells are cells that automatically express GFP (green fluorescent protein) in 3-5 
































Experimental Assay Procedure 
 
Experimental Procedure for the Control (0 vpc/µl), 500 000 vpc/µl and 1 million vpc/µl. 
 
1- 10mg/mL BSA was flowed through the desired reactor and channel and incubated for a few 
minutes to reduce nonspecific binding.  
 
2- 5-10 polystyrene goat anti-HIV-1 conjugated gp120 microsphere were flowed into the desired 
experiment channel and captured by the sieve valve. 
 
 
3- PBS (control)/500 000 vpc/µl or 1 million vpc/µl were flown into the channel with the 
microsphere and incubated for 15 minutes. 
 
4- Repeat Step 3 a total of 6 times.  
 
5- 10mg/mL BSA was introduced to the microsphere and incubated for 10 minutes. 
 
6- PBS was then flowed through the channel for 3 minutes. 
 
7- 4mg/mL goat anti-HIV-1 FITC was introduced and incubated for 10 minutes. 
 
8- PBS was flowed through for 3 minutes. 
 
9- Steps 7-8 was repeated a total of 10 times. 
 





















Figure 40: Graph showing the individual microsphere values (Blue diamond) and the overall average 
of all microspheres (Red diamond) for the control experiment. 
 
 























































Figure 41 A-C: Graph showing the individual microsphere values (Blue diamond) and the overall 


























































Thus, the average value for 500 000 vpc/µl is the average of the averages for the 3 experiments.  
A Fluorescence intensity (14). 
B Fluorescence intensity (11). 
C Fluorescence intensity (5). 






































Figure 42A-C: Graph showing the individual microsphere values (Blue diamond) and the overall 


























































Therefore, the average value for 1 million vpc/µl is the average of the averages for the 3 experiments.  
A Fluorescence intensity (19). 
B Fluorescence intensity (17).  
C Fluorescence intensity (21). 
The overall average fluorescence intensity was 19. 
 
*Note: The microspheres analysed for these experiments conducted were all microspheres that did not 






















Methodology for Assessing Different Blocking Agents 
  
1- A microsphere was incubated in either 10mg/mL BSA / 1mg/mL rabbit IgG antibody / 1mg/mL 
Goat IgG antibody or 10mg/mL casein for 15 minutes.  
2- Microsphere were washed with PBS. 
3- Thereafter the microspheres were subsequently incubated with Goat anti HIV-1 FITC detection 
antibody for 15 minutes.  
4- Microspheres were washed as in step 2.  
5- Fluorescence intensity was recorded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
